id	sid	tid	token	lemma	pos
cord-275349-b35pt3mo	1	1	key	key	NNP
cord-275349-b35pt3mo	1	2	:	:	:
cord-275349-b35pt3mo	1	3	cord-275349-b35pt3mo	cord-275349-b35pt3mo	NN
cord-275349-b35pt3mo	1	4	authors	author	NNS
cord-275349-b35pt3mo	1	5	:	:	:
cord-275349-b35pt3mo	1	6	Lenz	Lenz	NNP
cord-275349-b35pt3mo	1	7	,	,	,
cord-275349-b35pt3mo	1	8	Heinz	Heinz	NNP
cord-275349-b35pt3mo	1	9	-	-	HYPH
cord-275349-b35pt3mo	1	10	Josef	Josef	NNP
cord-275349-b35pt3mo	1	11	;	;	:
cord-275349-b35pt3mo	1	12	Richardson	Richardson	NNP
cord-275349-b35pt3mo	1	13	,	,	,
cord-275349-b35pt3mo	1	14	Peter	Peter	NNP
cord-275349-b35pt3mo	1	15	;	;	:
cord-275349-b35pt3mo	1	16	Stebbing	Stebbing	NNP
cord-275349-b35pt3mo	1	17	,	,	,
cord-275349-b35pt3mo	1	18	Justin	Justin	NNP
cord-275349-b35pt3mo	1	19	title	title	NN
cord-275349-b35pt3mo	1	20	:	:	:
cord-275349-b35pt3mo	1	21	The	the	DT
cord-275349-b35pt3mo	1	22	Emergence	Emergence	NNP
cord-275349-b35pt3mo	1	23	of	of	IN
cord-275349-b35pt3mo	1	24	Baricitinib	Baricitinib	NNP
cord-275349-b35pt3mo	1	25	:	:	:
cord-275349-b35pt3mo	1	26	A	a	DT
cord-275349-b35pt3mo	1	27	Story	Story	NNP
cord-275349-b35pt3mo	1	28	of	of	IN
cord-275349-b35pt3mo	1	29	Tortoises	Tortoises	NNPS
cord-275349-b35pt3mo	1	30	Versus	Versus	NNP
cord-275349-b35pt3mo	1	31	Hares	Hares	NNPS
cord-275349-b35pt3mo	1	32	date	date	NN
cord-275349-b35pt3mo	1	33	:	:	:
cord-275349-b35pt3mo	1	34	2020	2020	CD
cord-275349-b35pt3mo	1	35	-	-	HYPH
cord-275349-b35pt3mo	1	36	07	07	CD
cord-275349-b35pt3mo	1	37	-	-	HYPH
cord-275349-b35pt3mo	1	38	06	06	CD
cord-275349-b35pt3mo	1	39	journal	journal	NN
cord-275349-b35pt3mo	1	40	:	:	:
cord-275349-b35pt3mo	2	1	Clin	Clin	NNP
cord-275349-b35pt3mo	2	2	Infect	infect	VB
cord-275349-b35pt3mo	2	3	Dis	dis	NN
cord-275349-b35pt3mo	2	4	DOI	doi	NN
cord-275349-b35pt3mo	3	1	:	:	:
cord-275349-b35pt3mo	3	2	10.1093	10.1093	CD
cord-275349-b35pt3mo	3	3	/	/	SYM
cord-275349-b35pt3mo	3	4	cid	cid	NN
cord-275349-b35pt3mo	3	5	/	/	SYM
cord-275349-b35pt3mo	3	6	ciaa940	ciaa940	NNP
cord-275349-b35pt3mo	3	7	sha	sha	NNP
cord-275349-b35pt3mo	3	8	:	:	:
cord-275349-b35pt3mo	4	1	a79793fb975ca389ed75677309adb42386b80e17	a79793fb975ca389ed75677309adb42386b80e17	NNP
cord-275349-b35pt3mo	5	1	doc_id	doc_id	CD
cord-275349-b35pt3mo	6	1	:	:	:
cord-275349-b35pt3mo	6	2	275349	275349	CD
cord-275349-b35pt3mo	6	3	cord_uid	cord_uid	NNS
cord-275349-b35pt3mo	6	4	:	:	:
cord-275349-b35pt3mo	7	1	b35pt3mo	b35pt3mo	NNP
cord-275349-b35pt3mo	7	2	nan	nan	NNP
cord-275349-b35pt3mo	7	3	Keywords	Keywords	NNP
cord-275349-b35pt3mo	7	4	.	.	.
cord-275349-b35pt3mo	8	1	COVID-19	COVID-19	NNP
cord-275349-b35pt3mo	8	2	;	;	:
cord-275349-b35pt3mo	8	3	SARS	SARS	NNP
cord-275349-b35pt3mo	8	4	-	-	HYPH
cord-275349-b35pt3mo	8	5	CoV-2	CoV-2	NNP
cord-275349-b35pt3mo	8	6	;	;	:
cord-275349-b35pt3mo	8	7	barictinib	barictinib	NNP
cord-275349-b35pt3mo	8	8	;	;	:
cord-275349-b35pt3mo	8	9	anti	anti	JJ
cord-275349-b35pt3mo	8	10	-	-	JJ
cord-275349-b35pt3mo	8	11	viral	viral	JJ
cord-275349-b35pt3mo	8	12	;	;	:
cord-275349-b35pt3mo	8	13	cytokine	cytokine	NN
cord-275349-b35pt3mo	8	14	storm	storm	NN
cord-275349-b35pt3mo	8	15	;	;	:
cord-275349-b35pt3mo	8	16	trial	trial	NN
cord-275349-b35pt3mo	8	17	.	.	.
cord-275349-b35pt3mo	9	1	Baricitinib	Baricitinib	NNP
cord-275349-b35pt3mo	9	2	is	be	VBZ
cord-275349-b35pt3mo	9	3	a	a	DT
cord-275349-b35pt3mo	9	4	once	once	RB
cord-275349-b35pt3mo	9	5	daily	daily	RB
cord-275349-b35pt3mo	9	6	orally	orally	RB
cord-275349-b35pt3mo	9	7	administered	administer	VBD
cord-275349-b35pt3mo	9	8	JAK1/2	JAK1/2	NNP
cord-275349-b35pt3mo	9	9	inhibitor	inhibitor	NN
cord-275349-b35pt3mo	9	10	,	,	,
cord-275349-b35pt3mo	9	11	which	which	WDT
cord-275349-b35pt3mo	9	12	inhibits	inhibit	VBZ
cord-275349-b35pt3mo	9	13	the	the	DT
cord-275349-b35pt3mo	9	14	signaling	signaling	NN
cord-275349-b35pt3mo	9	15	of	of	IN
cord-275349-b35pt3mo	9	16	many	many	JJ
cord-275349-b35pt3mo	9	17	cytokines	cytokine	NNS
cord-275349-b35pt3mo	9	18	and	and	CC
cord-275349-b35pt3mo	9	19	has	have	VBZ
cord-275349-b35pt3mo	9	20	been	be	VBN
cord-275349-b35pt3mo	9	21	approved	approve	VBN
cord-275349-b35pt3mo	9	22	for	for	IN
cord-275349-b35pt3mo	9	23	the	the	DT
cord-275349-b35pt3mo	9	24	treatment	treatment	NN
cord-275349-b35pt3mo	9	25	of	of	IN
cord-275349-b35pt3mo	9	26	moderate	moderate	JJ
cord-275349-b35pt3mo	9	27	to	to	IN
cord-275349-b35pt3mo	9	28	severe	severe	JJ
cord-275349-b35pt3mo	9	29	rheumatoid	rheumatoid	NN
cord-275349-b35pt3mo	9	30	arthritis	arthritis	NN
cord-275349-b35pt3mo	9	31	(	(	-LRB-
cord-275349-b35pt3mo	9	32	RA	RA	NNP
cord-275349-b35pt3mo	9	33	)	)	-RRB-
cord-275349-b35pt3mo	9	34	based	base	VBN
cord-275349-b35pt3mo	9	35	on	on	IN
cord-275349-b35pt3mo	9	36	long	long	JJ
cord-275349-b35pt3mo	9	37	-	-	HYPH
cord-275349-b35pt3mo	9	38	term	term	NN
cord-275349-b35pt3mo	9	39	randomized	randomize	VBN
cord-275349-b35pt3mo	9	40	dosing	dosing	NN
cord-275349-b35pt3mo	9	41	against	against	IN
cord-275349-b35pt3mo	9	42	both	both	DT
cord-275349-b35pt3mo	9	43	placebo	placebo	NN
cord-275349-b35pt3mo	9	44	and	and	CC
cord-275349-b35pt3mo	9	45	standard	standard	NN
cord-275349-b35pt3mo	9	46	of	of	IN
cord-275349-b35pt3mo	9	47	care	care	NN
cord-275349-b35pt3mo	9	48	[	[	-LRB-
cord-275349-b35pt3mo	9	49	1	1	CD
cord-275349-b35pt3mo	9	50	]	]	-RRB-
cord-275349-b35pt3mo	9	51	,	,	,
cord-275349-b35pt3mo	9	52	notably	notably	RB
cord-275349-b35pt3mo	9	53	tumor	tumor	NN
cord-275349-b35pt3mo	9	54	necrosis	necrosis	NN
cord-275349-b35pt3mo	9	55	factor	factor	NN
cord-275349-b35pt3mo	9	56	(	(	-LRB-
cord-275349-b35pt3mo	9	57	TNF)alpha	tnf)alpha	CD
cord-275349-b35pt3mo	9	58	blockade	blockade	NN
cord-275349-b35pt3mo	9	59	.	.	.
cord-275349-b35pt3mo	10	1	Its	-PRON-	PRP$
cord-275349-b35pt3mo	10	2	use	use	NN
cord-275349-b35pt3mo	10	3	for	for	IN
cord-275349-b35pt3mo	10	4	the	the	DT
cord-275349-b35pt3mo	10	5	treatment	treatment	NN
cord-275349-b35pt3mo	10	6	of	of	IN
cord-275349-b35pt3mo	10	7	coronavirus	coronavirus	NN
cord-275349-b35pt3mo	10	8	disease	disease	NN
cord-275349-b35pt3mo	10	9	2019	2019	CD
cord-275349-b35pt3mo	10	10	(	(	-LRB-
cord-275349-b35pt3mo	10	11	COVID-19	COVID-19	NNP
cord-275349-b35pt3mo	10	12	)	)	-RRB-
cord-275349-b35pt3mo	10	13	was	be	VBD
cord-275349-b35pt3mo	10	14	originally	originally	RB
cord-275349-b35pt3mo	10	15	suggested	suggest	VBN
cord-275349-b35pt3mo	10	16	after	after	IN
cord-275349-b35pt3mo	10	17	a	a	DT
cord-275349-b35pt3mo	10	18	search	search	NN
cord-275349-b35pt3mo	10	19	of	of	IN
cord-275349-b35pt3mo	10	20	the	the	DT
cord-275349-b35pt3mo	10	21	extensive	extensive	JJ
cord-275349-b35pt3mo	10	22	BenevolentAI	benevolentai	JJ
cord-275349-b35pt3mo	10	23	knowledge	knowledge	NN
cord-275349-b35pt3mo	10	24	graph	graph	NN
cord-275349-b35pt3mo	10	25	for	for	IN
cord-275349-b35pt3mo	10	26	approved	approve	VBN
cord-275349-b35pt3mo	10	27	drugs	drug	NNS
cord-275349-b35pt3mo	10	28	that	that	WDT
cord-275349-b35pt3mo	10	29	could	could	MD
cord-275349-b35pt3mo	10	30	be	be	VB
cord-275349-b35pt3mo	10	31	used	use	VBN
cord-275349-b35pt3mo	10	32	in	in	IN
cord-275349-b35pt3mo	10	33	this	this	DT
cord-275349-b35pt3mo	10	34	pandemic	pandemic	NN
cord-275349-b35pt3mo	10	35	[	[	-LRB-
cord-275349-b35pt3mo	10	36	2	2	CD
cord-275349-b35pt3mo	10	37	]	]	-RRB-
cord-275349-b35pt3mo	10	38	.	.	.
cord-275349-b35pt3mo	11	1	An	an	DT
cord-275349-b35pt3mo	11	2	advantage	advantage	NN
cord-275349-b35pt3mo	11	3	of	of	IN
cord-275349-b35pt3mo	11	4	approved	approve	VBN
cord-275349-b35pt3mo	11	5	drugs	drug	NNS
cord-275349-b35pt3mo	11	6	is	be	VBZ
cord-275349-b35pt3mo	11	7	that	that	IN
cord-275349-b35pt3mo	11	8	they	-PRON-	PRP
cord-275349-b35pt3mo	11	9	have	have	VBP
cord-275349-b35pt3mo	11	10	a	a	DT
cord-275349-b35pt3mo	11	11	known	know	VBN
cord-275349-b35pt3mo	11	12	safety	safety	NN
cord-275349-b35pt3mo	11	13	profile	profile	NN
cord-275349-b35pt3mo	11	14	and	and	CC
cord-275349-b35pt3mo	11	15	can	can	MD
cord-275349-b35pt3mo	11	16	therefore	therefore	RB
cord-275349-b35pt3mo	11	17	be	be	VB
cord-275349-b35pt3mo	11	18	rapidly	rapidly	RB
cord-275349-b35pt3mo	11	19	approved	approve	VBN
cord-275349-b35pt3mo	11	20	in	in	IN
cord-275349-b35pt3mo	11	21	fast	fast	JJ
cord-275349-b35pt3mo	11	22	moving	move	VBG
cord-275349-b35pt3mo	11	23	pandemics	pandemic	NNS
cord-275349-b35pt3mo	11	24	.	.	.
cord-275349-b35pt3mo	12	1	The	the	DT
cord-275349-b35pt3mo	12	2	artificial	artificial	JJ
cord-275349-b35pt3mo	12	3	intelligence	intelligence	NN
cord-275349-b35pt3mo	12	4	algorithms	algorithm	NNS
cord-275349-b35pt3mo	12	5	predicted	predict	VBD
cord-275349-b35pt3mo	12	6	that	that	IN
cord-275349-b35pt3mo	12	7	baricitinib	baricitinib	NN
cord-275349-b35pt3mo	12	8	would	would	MD
cord-275349-b35pt3mo	12	9	inhibit	inhibit	VB
cord-275349-b35pt3mo	12	10	severe	severe	JJ
cord-275349-b35pt3mo	12	11	acute	acute	JJ
cord-275349-b35pt3mo	12	12	respiratory	respiratory	JJ
cord-275349-b35pt3mo	12	13	syndrome	syndrome	NN
cord-275349-b35pt3mo	12	14	coronavirus	coronavirus	NN
cord-275349-b35pt3mo	12	15	2	2	CD
cord-275349-b35pt3mo	13	1	(	(	-LRB-
cord-275349-b35pt3mo	13	2	SARS	SARS	NNP
cord-275349-b35pt3mo	13	3	-	-	HYPH
cord-275349-b35pt3mo	13	4	CoV-2	CoV-2	NNP
cord-275349-b35pt3mo	13	5	)	)	-RRB-
cord-275349-b35pt3mo	13	6	infection	infection	NN
cord-275349-b35pt3mo	13	7	of	of	IN
cord-275349-b35pt3mo	13	8	cells	cell	NNS
cord-275349-b35pt3mo	13	9	[	[	-LRB-
cord-275349-b35pt3mo	13	10	2	2	CD
cord-275349-b35pt3mo	13	11	]	]	-RRB-
cord-275349-b35pt3mo	13	12	,	,	,
cord-275349-b35pt3mo	13	13	(	(	-LRB-
cord-275349-b35pt3mo	13	14	an	an	DT
cord-275349-b35pt3mo	13	15	effect	effect	NN
cord-275349-b35pt3mo	13	16	later	later	RB
cord-275349-b35pt3mo	13	17	confirmed	confirm	VBN
cord-275349-b35pt3mo	13	18	in	in	IN
cord-275349-b35pt3mo	13	19	human	human	JJ
cord-275349-b35pt3mo	13	20	liver	liver	NN
cord-275349-b35pt3mo	13	21	spheroids	spheroid	NNS
cord-275349-b35pt3mo	13	22	)	)	-RRB-
cord-275349-b35pt3mo	13	23	[	[	-LRB-
cord-275349-b35pt3mo	13	24	3	3	CD
cord-275349-b35pt3mo	13	25	]	]	-RRB-
cord-275349-b35pt3mo	13	26	,	,	,
cord-275349-b35pt3mo	13	27	combined	combine	VBN
cord-275349-b35pt3mo	13	28	with	with	IN
cord-275349-b35pt3mo	13	29	its	-PRON-	PRP$
cord-275349-b35pt3mo	13	30	better	well	RBR
cord-275349-b35pt3mo	13	31	-	-	HYPH
cord-275349-b35pt3mo	13	32	known	know	VBN
cord-275349-b35pt3mo	13	33	anti	anti	JJ
cord-275349-b35pt3mo	13	34	-	-	JJ
cord-275349-b35pt3mo	13	35	inflammatory	inflammatory	JJ
cord-275349-b35pt3mo	13	36	properties	property	NNS
cord-275349-b35pt3mo	13	37	.	.	.
cord-275349-b35pt3mo	14	1	The	the	DT
cord-275349-b35pt3mo	14	2	doses	dose	NNS
cord-275349-b35pt3mo	14	3	required	require	VBN
cord-275349-b35pt3mo	14	4	were	be	VBD
cord-275349-b35pt3mo	14	5	predicted	predict	VBN
cord-275349-b35pt3mo	14	6	to	to	TO
cord-275349-b35pt3mo	14	7	be	be	VB
cord-275349-b35pt3mo	14	8	the	the	DT
cord-275349-b35pt3mo	14	9	same	same	JJ
cord-275349-b35pt3mo	14	10	as	as	IN
cord-275349-b35pt3mo	14	11	used	use	VBN
cord-275349-b35pt3mo	14	12	for	for	IN
cord-275349-b35pt3mo	14	13	the	the	DT
cord-275349-b35pt3mo	14	14	treatment	treatment	NN
cord-275349-b35pt3mo	14	15	of	of	IN
cord-275349-b35pt3mo	14	16	RA	RA	NNP
cord-275349-b35pt3mo	14	17	.	.	.
cord-275349-b35pt3mo	15	1	At	at	IN
cord-275349-b35pt3mo	15	2	these	these	DT
cord-275349-b35pt3mo	15	3	doses	dose	NNS
cord-275349-b35pt3mo	15	4	,	,	,
cord-275349-b35pt3mo	15	5	interleukin	interleukin	NN
cord-275349-b35pt3mo	15	6	6	6	CD
cord-275349-b35pt3mo	15	7	(	(	-LRB-
cord-275349-b35pt3mo	15	8	IL-6	IL-6	NNP
cord-275349-b35pt3mo	15	9	)	)	-RRB-
cord-275349-b35pt3mo	15	10	levels	level	NNS
cord-275349-b35pt3mo	15	11	were	be	VBD
cord-275349-b35pt3mo	15	12	reduced	reduce	VBN
cord-275349-b35pt3mo	15	13	both	both	CC
cord-275349-b35pt3mo	15	14	in	in	IN
cord-275349-b35pt3mo	15	15	COVID19	covid19	NN
cord-275349-b35pt3mo	15	16	patients	patient	NNS
cord-275349-b35pt3mo	15	17	as	as	RB
cord-275349-b35pt3mo	15	18	well	well	RB
cord-275349-b35pt3mo	15	19	as	as	IN
cord-275349-b35pt3mo	15	20	dose	dose	NN
cord-275349-b35pt3mo	15	21	dependently	dependently	RB
cord-275349-b35pt3mo	15	22	in	in	IN
cord-275349-b35pt3mo	15	23	RA	RA	NNP
cord-275349-b35pt3mo	15	24	patients	patient	NNS
cord-275349-b35pt3mo	15	25	in	in	IN
cord-275349-b35pt3mo	15	26	a	a	DT
cord-275349-b35pt3mo	15	27	previous	previous	JJ
cord-275349-b35pt3mo	15	28	phase	phase	NN
cord-275349-b35pt3mo	15	29	2b	2b	CD
cord-275349-b35pt3mo	15	30	randomized	randomized	JJ
cord-275349-b35pt3mo	15	31	RA	RA	NNP
cord-275349-b35pt3mo	15	32	trial	trial	NN
cord-275349-b35pt3mo	15	33	,	,	,
cord-275349-b35pt3mo	15	34	the	the	DT
cord-275349-b35pt3mo	15	35	first	first	JJ
cord-275349-b35pt3mo	15	36	time	time	NN
cord-275349-b35pt3mo	15	37	this	this	DT
cord-275349-b35pt3mo	15	38	was	be	VBD
cord-275349-b35pt3mo	15	39	shown	show	VBN
cord-275349-b35pt3mo	15	40	in	in	IN
cord-275349-b35pt3mo	15	41	humans	human	NNS
cord-275349-b35pt3mo	15	42	[	[	-LRB-
cord-275349-b35pt3mo	15	43	4	4	CD
cord-275349-b35pt3mo	15	44	]	]	-RRB-
cord-275349-b35pt3mo	15	45	.	.	.
cord-275349-b35pt3mo	16	1	What	what	WP
cord-275349-b35pt3mo	16	2	was	be	VBD
cord-275349-b35pt3mo	16	3	more	more	RBR
cord-275349-b35pt3mo	16	4	intriguing	intriguing	JJ
cord-275349-b35pt3mo	16	5	was	be	VBD
cord-275349-b35pt3mo	16	6	its	-PRON-	PRP$
cord-275349-b35pt3mo	16	7	inhibition	inhibition	NN
cord-275349-b35pt3mo	16	8	of	of	IN
cord-275349-b35pt3mo	16	9	members	member	NNS
cord-275349-b35pt3mo	16	10	of	of	IN
cord-275349-b35pt3mo	16	11	the	the	DT
cord-275349-b35pt3mo	16	12	numb	numb	JJ
cord-275349-b35pt3mo	16	13	associated	associate	VBN
cord-275349-b35pt3mo	16	14	kinase	kinase	NN
cord-275349-b35pt3mo	16	15	family	family	NN
cord-275349-b35pt3mo	16	16	,	,	,
cord-275349-b35pt3mo	16	17	thought	think	VBN
cord-275349-b35pt3mo	16	18	in	in	IN
cord-275349-b35pt3mo	16	19	turn	turn	NN
cord-275349-b35pt3mo	16	20	to	to	TO
cord-275349-b35pt3mo	16	21	translate	translate	VB
cord-275349-b35pt3mo	16	22	to	to	IN
cord-275349-b35pt3mo	16	23	reduced	reduce	VBN
cord-275349-b35pt3mo	16	24	AP-2	AP-2	NNP
cord-275349-b35pt3mo	16	25	mediated	mediate	VBN
cord-275349-b35pt3mo	16	26	viral	viral	JJ
cord-275349-b35pt3mo	16	27	propagation	propagation	NN
cord-275349-b35pt3mo	16	28	early	early	RB
cord-275349-b35pt3mo	16	29	in	in	IN
cord-275349-b35pt3mo	16	30	the	the	DT
cord-275349-b35pt3mo	16	31	infectious	infectious	JJ
cord-275349-b35pt3mo	16	32	cycle	cycle	NN
cord-275349-b35pt3mo	16	33	,	,	,
cord-275349-b35pt3mo	16	34	suggesting	suggest	VBG
cord-275349-b35pt3mo	16	35	antiviral	antiviral	JJ
cord-275349-b35pt3mo	16	36	activity	activity	NN
cord-275349-b35pt3mo	16	37	;	;	:
cord-275349-b35pt3mo	16	38	this	this	DT
cord-275349-b35pt3mo	16	39	was	be	VBD
cord-275349-b35pt3mo	16	40	shown	show	VBN
cord-275349-b35pt3mo	16	41	in	in	IN
cord-275349-b35pt3mo	16	42	liver	liver	NN
cord-275349-b35pt3mo	16	43	spheroid	spheroid	NN
cord-275349-b35pt3mo	16	44	models	model	NNS
cord-275349-b35pt3mo	16	45	,	,	,
cord-275349-b35pt3mo	16	46	which	which	WDT
cord-275349-b35pt3mo	16	47	express	express	VBP
cord-275349-b35pt3mo	16	48	detectable	detectable	JJ
cord-275349-b35pt3mo	16	49	albeit	albeit	IN
cord-275349-b35pt3mo	16	50	low	low	JJ
cord-275349-b35pt3mo	16	51	levels	level	NNS
cord-275349-b35pt3mo	16	52	of	of	IN
cord-275349-b35pt3mo	16	53	the	the	DT
cord-275349-b35pt3mo	16	54	ACE2	ACE2	NNP
cord-275349-b35pt3mo	16	55	receptor	receptor	NN
cord-275349-b35pt3mo	16	56	.	.	.
cord-275349-b35pt3mo	17	1	In	in	IN
cord-275349-b35pt3mo	17	2	hospitalized	hospitalize	VBN
cord-275349-b35pt3mo	17	3	patients	patient	NNS
cord-275349-b35pt3mo	17	4	it	-PRON-	PRP
cord-275349-b35pt3mo	17	5	is	be	VBZ
cord-275349-b35pt3mo	17	6	anticipated	anticipate	VBN
cord-275349-b35pt3mo	17	7	that	that	IN
cord-275349-b35pt3mo	17	8	residual	residual	JJ
cord-275349-b35pt3mo	17	9	virus	virus	NN
cord-275349-b35pt3mo	17	10	that	that	WDT
cord-275349-b35pt3mo	17	11	propagates	propagate	VBZ
cord-275349-b35pt3mo	17	12	itself	-PRON-	PRP
cord-275349-b35pt3mo	17	13	in	in	IN
cord-275349-b35pt3mo	17	14	airway	airway	NN
cord-275349-b35pt3mo	17	15	epithelial	epithelial	JJ
cord-275349-b35pt3mo	17	16	tissues	tissue	NNS
cord-275349-b35pt3mo	17	17	maintains	maintain	VBZ
cord-275349-b35pt3mo	17	18	and	and	CC
cord-275349-b35pt3mo	17	19	amplifies	amplify	VBZ
cord-275349-b35pt3mo	17	20	the	the	DT
cord-275349-b35pt3mo	17	21	exaggerated	exaggerated	JJ
cord-275349-b35pt3mo	17	22	inflammatory	inflammatory	JJ
cord-275349-b35pt3mo	17	23	response	response	NN
cord-275349-b35pt3mo	17	24	typical	typical	JJ
cord-275349-b35pt3mo	17	25	of	of	IN
cord-275349-b35pt3mo	17	26	COVID-19	COVID-19	NNP
cord-275349-b35pt3mo	17	27	.	.	.
cord-275349-b35pt3mo	18	1	Consequently	consequently	RB
cord-275349-b35pt3mo	18	2	,	,	,
cord-275349-b35pt3mo	18	3	the	the	DT
cord-275349-b35pt3mo	18	4	combined	combine	VBN
cord-275349-b35pt3mo	18	5	potential	potential	JJ
cord-275349-b35pt3mo	18	6	antiviral	antiviral	JJ
cord-275349-b35pt3mo	18	7	and	and	CC
cord-275349-b35pt3mo	18	8	anti	anti	JJ
cord-275349-b35pt3mo	18	9	-	-	JJ
cord-275349-b35pt3mo	18	10	inflammatory	inflammatory	JJ
cord-275349-b35pt3mo	18	11	effects	effect	NNS
cord-275349-b35pt3mo	18	12	of	of	IN
cord-275349-b35pt3mo	18	13	this	this	DT
cord-275349-b35pt3mo	18	14	dually	dually	RB
cord-275349-b35pt3mo	18	15	acting	act	VBG
cord-275349-b35pt3mo	18	16	drug	drug	NN
cord-275349-b35pt3mo	18	17	could	could	MD
cord-275349-b35pt3mo	18	18	be	be	VB
cord-275349-b35pt3mo	18	19	ideal	ideal	JJ
cord-275349-b35pt3mo	18	20	for	for	IN
cord-275349-b35pt3mo	18	21	halting	halt	VBG
cord-275349-b35pt3mo	18	22	the	the	DT
cord-275349-b35pt3mo	18	23	progression	progression	NN
cord-275349-b35pt3mo	18	24	of	of	IN
cord-275349-b35pt3mo	18	25	the	the	DT
cord-275349-b35pt3mo	18	26	disease	disease	NN
cord-275349-b35pt3mo	18	27	in	in	IN
cord-275349-b35pt3mo	18	28	hospitalized	hospitalize	VBN
cord-275349-b35pt3mo	18	29	patients	patient	NNS
cord-275349-b35pt3mo	18	30	,	,	,
cord-275349-b35pt3mo	18	31	when	when	WRB
cord-275349-b35pt3mo	18	32	taken	take	VBN
cord-275349-b35pt3mo	18	33	for	for	IN
cord-275349-b35pt3mo	18	34	a	a	DT
cord-275349-b35pt3mo	18	35	limited	limited	JJ
cord-275349-b35pt3mo	18	36	duration	duration	NN
cord-275349-b35pt3mo	18	37	.	.	.
cord-275349-b35pt3mo	19	1	At	at	IN
cord-275349-b35pt3mo	19	2	the	the	DT
cord-275349-b35pt3mo	19	3	University	University	NNP
cord-275349-b35pt3mo	19	4	of	of	IN
cord-275349-b35pt3mo	19	5	Southern	Southern	NNP
cord-275349-b35pt3mo	19	6	California	California	NNP
cord-275349-b35pt3mo	19	7	now	now	RB
cord-275349-b35pt3mo	19	8	,	,	,
cord-275349-b35pt3mo	19	9	a	a	DT
cord-275349-b35pt3mo	19	10	randomized	randomized	JJ
cord-275349-b35pt3mo	19	11	placebo	placebo	NN
cord-275349-b35pt3mo	19	12	-	-	HYPH
cord-275349-b35pt3mo	19	13	controlled	control	VBN
cord-275349-b35pt3mo	19	14	phase	phase	NN
cord-275349-b35pt3mo	19	15	2	2	CD
cord-275349-b35pt3mo	19	16	study	study	NN
cord-275349-b35pt3mo	19	17	with	with	IN
cord-275349-b35pt3mo	19	18	remdesivir	remdesivir	NNP
cord-275349-b35pt3mo	19	19	with	with	IN
cord-275349-b35pt3mo	19	20	/	/	SYM
cord-275349-b35pt3mo	19	21	without	without	IN
cord-275349-b35pt3mo	19	22	baricitinib	baricitinib	NNP
cord-275349-b35pt3mo	19	23	is	be	VBZ
cord-275349-b35pt3mo	19	24	ongoing	ongoing	JJ
cord-275349-b35pt3mo	19	25	to	to	TO
cord-275349-b35pt3mo	19	26	test	test	VB
cord-275349-b35pt3mo	19	27	the	the	DT
cord-275349-b35pt3mo	19	28	efficacy	efficacy	NN
cord-275349-b35pt3mo	19	29	to	to	TO
cord-275349-b35pt3mo	19	30	prevent	prevent	VB
cord-275349-b35pt3mo	19	31	mechanical	mechanical	JJ
cord-275349-b35pt3mo	19	32	ventilation	ventilation	NN
cord-275349-b35pt3mo	19	33	including	include	VBG
cord-275349-b35pt3mo	19	34	significant	significant	JJ
cord-275349-b35pt3mo	19	35	biomarker	biomarker	NN
cord-275349-b35pt3mo	19	36	research	research	NN
cord-275349-b35pt3mo	19	37	.	.	.
cord-275349-b35pt3mo	20	1	In	in	IN
cord-275349-b35pt3mo	20	2	this	this	DT
cord-275349-b35pt3mo	20	3	issue	issue	NN
cord-275349-b35pt3mo	20	4	of	of	IN
cord-275349-b35pt3mo	20	5	Clinical	Clinical	NNP
cord-275349-b35pt3mo	20	6	Infectious	Infectious	NNP
cord-275349-b35pt3mo	20	7	Diseases	Diseases	NNPS
cord-275349-b35pt3mo	20	8	,	,	,
cord-275349-b35pt3mo	20	9	Titanji	Titanji	NNP
cord-275349-b35pt3mo	20	10	et	et	FW
cord-275349-b35pt3mo	20	11	al	al	NNP
cord-275349-b35pt3mo	20	12	describe	describe	VB
cord-275349-b35pt3mo	20	13	the	the	DT
cord-275349-b35pt3mo	20	14	outcome	outcome	NN
cord-275349-b35pt3mo	20	15	of	of	IN
cord-275349-b35pt3mo	20	16	15	15	CD
cord-275349-b35pt3mo	20	17	moderate	moderate	JJ
cord-275349-b35pt3mo	20	18	-	-	HYPH
cord-275349-b35pt3mo	20	19	to	to	TO
cord-275349-b35pt3mo	20	20	-	-	HYPH
cord-275349-b35pt3mo	20	21	critically	critically	RB
cord-275349-b35pt3mo	20	22	ill	ill	JJ
cord-275349-b35pt3mo	20	23	patients	patient	NNS
cord-275349-b35pt3mo	20	24	with	with	IN
cord-275349-b35pt3mo	20	25	COVID-19	COVID-19	NNP
cord-275349-b35pt3mo	20	26	treated	treat	VBN
cord-275349-b35pt3mo	20	27	with	with	IN
cord-275349-b35pt3mo	20	28	baricitinib	baricitinib	NNP
cord-275349-b35pt3mo	20	29	and	and	CC
cord-275349-b35pt3mo	20	30	hydroxychloroquine	hydroxychloroquine	NN
cord-275349-b35pt3mo	20	31	.	.	.
cord-275349-b35pt3mo	21	1	This	this	DT
cord-275349-b35pt3mo	21	2	therapy	therapy	NN
cord-275349-b35pt3mo	21	3	was	be	VBD
cord-275349-b35pt3mo	21	4	associated	associate	VBN
cord-275349-b35pt3mo	21	5	with	with	IN
cord-275349-b35pt3mo	21	6	a	a	DT
cord-275349-b35pt3mo	21	7	reduction	reduction	NN
cord-275349-b35pt3mo	21	8	in	in	IN
cord-275349-b35pt3mo	21	9	inflammatory	inflammatory	JJ
cord-275349-b35pt3mo	21	10	markers	marker	NNS
cord-275349-b35pt3mo	21	11	including	include	VBG
cord-275349-b35pt3mo	21	12	fever	fever	NN
cord-275349-b35pt3mo	21	13	,	,	,
cord-275349-b35pt3mo	21	14	C	C	NNP
cord-275349-b35pt3mo	21	15	reactive	reactive	JJ
cord-275349-b35pt3mo	21	16	protein	protein	NN
cord-275349-b35pt3mo	21	17	(	(	-LRB-
cord-275349-b35pt3mo	21	18	CRP	CRP	NNP
cord-275349-b35pt3mo	21	19	)	)	-RRB-
cord-275349-b35pt3mo	21	20	,	,	,
cord-275349-b35pt3mo	21	21	improvement	improvement	NN
cord-275349-b35pt3mo	21	22	of	of	IN
cord-275349-b35pt3mo	21	23	oxygen	oxygen	NN
cord-275349-b35pt3mo	21	24	requirements	requirement	NNS
cord-275349-b35pt3mo	21	25	,	,	,
cord-275349-b35pt3mo	21	26	and	and	CC
cord-275349-b35pt3mo	21	27	recovery	recovery	NN
cord-275349-b35pt3mo	21	28	in	in	IN
cord-275349-b35pt3mo	21	29	12	12	CD
cord-275349-b35pt3mo	21	30	of	of	IN
cord-275349-b35pt3mo	21	31	the	the	DT
cord-275349-b35pt3mo	21	32	15	15	CD
cord-275349-b35pt3mo	21	33	(	(	-LRB-
cord-275349-b35pt3mo	21	34	80	80	CD
cord-275349-b35pt3mo	21	35	%	%	NN
cord-275349-b35pt3mo	21	36	)	)	-RRB-
cord-275349-b35pt3mo	21	37	patients	patient	NNS
cord-275349-b35pt3mo	21	38	studied	study	VBD
cord-275349-b35pt3mo	21	39	.	.	.
cord-275349-b35pt3mo	22	1	Although	although	IN
cord-275349-b35pt3mo	22	2	it	-PRON-	PRP
cord-275349-b35pt3mo	22	3	is	be	VBZ
cord-275349-b35pt3mo	22	4	possible	possible	JJ
cord-275349-b35pt3mo	22	5	that	that	IN
cord-275349-b35pt3mo	22	6	the	the	DT
cord-275349-b35pt3mo	22	7	antiviral	antiviral	JJ
cord-275349-b35pt3mo	22	8	and	and	CC
cord-275349-b35pt3mo	22	9	anti	anti	JJ
cord-275349-b35pt3mo	22	10	-	-	JJ
cord-275349-b35pt3mo	22	11	inflammatory	inflammatory	JJ
cord-275349-b35pt3mo	22	12	effects	effect	NNS
cord-275349-b35pt3mo	22	13	of	of	IN
cord-275349-b35pt3mo	22	14	hydroxychloroquine	hydroxychloroquine	NN
cord-275349-b35pt3mo	22	15	contributed	contribute	VBD
cord-275349-b35pt3mo	22	16	to	to	IN
cord-275349-b35pt3mo	22	17	this	this	DT
cord-275349-b35pt3mo	22	18	positive	positive	JJ
cord-275349-b35pt3mo	22	19	outcome	outcome	NN
cord-275349-b35pt3mo	22	20	,	,	,
cord-275349-b35pt3mo	22	21	this	this	DT
cord-275349-b35pt3mo	22	22	would	would	MD
cord-275349-b35pt3mo	22	23	seem	seem	VB
cord-275349-b35pt3mo	22	24	unlikely	unlikely	JJ
cord-275349-b35pt3mo	22	25	according	accord	VBG
cord-275349-b35pt3mo	22	26	to	to	IN
cord-275349-b35pt3mo	22	27	the	the	DT
cord-275349-b35pt3mo	22	28	recently	recently	RB
cord-275349-b35pt3mo	22	29	reported	report	VBN
cord-275349-b35pt3mo	22	30	National	National	NNP
cord-275349-b35pt3mo	22	31	Institutes	Institutes	NNPS
cord-275349-b35pt3mo	22	32	of	of	IN
cord-275349-b35pt3mo	22	33	Health	Health	NNP
cord-275349-b35pt3mo	22	34	(	(	-LRB-
cord-275349-b35pt3mo	22	35	NIH	NIH	NNP
cord-275349-b35pt3mo	22	36	)	)	-RRB-
cord-275349-b35pt3mo	22	37	randomized	randomized	JJ
cord-275349-b35pt3mo	22	38	trials	trial	NNS
cord-275349-b35pt3mo	22	39	)	)	-RRB-
cord-275349-b35pt3mo	22	40	[	[	-LRB-
cord-275349-b35pt3mo	22	41	5	5	CD
cord-275349-b35pt3mo	22	42	]	]	-RRB-
cord-275349-b35pt3mo	22	43	,	,	,
cord-275349-b35pt3mo	22	44	among	among	IN
cord-275349-b35pt3mo	22	45	many	many	JJ
cord-275349-b35pt3mo	22	46	other	other	JJ
cord-275349-b35pt3mo	22	47	studies	study	NNS
cord-275349-b35pt3mo	22	48	.	.	.
cord-275349-b35pt3mo	23	1	This	this	DT
cord-275349-b35pt3mo	23	2	new	new	JJ
cord-275349-b35pt3mo	23	3	paper	paper	NN
cord-275349-b35pt3mo	23	4	in	in	IN
cord-275349-b35pt3mo	23	5	the	the	DT
cord-275349-b35pt3mo	23	6	journal	journal	NN
cord-275349-b35pt3mo	23	7	extends	extend	VBZ
cord-275349-b35pt3mo	23	8	the	the	DT
cord-275349-b35pt3mo	23	9	previous	previous	JJ
cord-275349-b35pt3mo	23	10	published	publish	VBN
cord-275349-b35pt3mo	23	11	reports	report	NNS
cord-275349-b35pt3mo	23	12	of	of	IN
cord-275349-b35pt3mo	23	13	baricitinib	baricitinib	NN
cord-275349-b35pt3mo	23	14	treatment	treatment	NN
cord-275349-b35pt3mo	23	15	in	in	IN
cord-275349-b35pt3mo	23	16	mild	mild	JJ
cord-275349-b35pt3mo	23	17	-	-	HYPH
cord-275349-b35pt3mo	23	18	tomoderate	tomoderate	NN
cord-275349-b35pt3mo	23	19	COVID19	covid19	NN
cord-275349-b35pt3mo	23	20	patients	patient	NNS
cord-275349-b35pt3mo	23	21	and	and	CC
cord-275349-b35pt3mo	23	22	provides	provide	VBZ
cord-275349-b35pt3mo	23	23	further	further	JJ
cord-275349-b35pt3mo	23	24	evidence	evidence	NN
cord-275349-b35pt3mo	23	25	that	that	IN
cord-275349-b35pt3mo	23	26	baricitinib	baricitinib	NN
cord-275349-b35pt3mo	23	27	could	could	MD
cord-275349-b35pt3mo	23	28	be	be	VB
cord-275349-b35pt3mo	23	29	a	a	DT
cord-275349-b35pt3mo	23	30	potential	potential	JJ
cord-275349-b35pt3mo	23	31	treatment	treatment	NN
cord-275349-b35pt3mo	23	32	for	for	IN
cord-275349-b35pt3mo	23	33	unwell	unwell	RB
cord-275349-b35pt3mo	23	34	hospitalized	hospitalize	VBN
cord-275349-b35pt3mo	23	35	patients	patient	NNS
cord-275349-b35pt3mo	23	36	with	with	IN
cord-275349-b35pt3mo	23	37	this	this	DT
cord-275349-b35pt3mo	23	38	disease	disease	NN
cord-275349-b35pt3mo	23	39	,	,	,
cord-275349-b35pt3mo	23	40	independent	independent	JJ
cord-275349-b35pt3mo	23	41	of	of	IN
cord-275349-b35pt3mo	23	42	severity	severity	NN
cord-275349-b35pt3mo	23	43	.	.	.
cord-275349-b35pt3mo	24	1	Indeed	indeed	RB
cord-275349-b35pt3mo	24	2	,	,	,
cord-275349-b35pt3mo	24	3	in	in	IN
cord-275349-b35pt3mo	24	4	mild	mild	NN
cord-275349-b35pt3mo	24	5	-	-	HYPH
cord-275349-b35pt3mo	24	6	to	to	IN
cord-275349-b35pt3mo	24	7	-	-	HYPH
cord-275349-b35pt3mo	24	8	moderate	moderate	JJ
cord-275349-b35pt3mo	24	9	patients	patient	NNS
cord-275349-b35pt3mo	24	10	,	,	,
cord-275349-b35pt3mo	24	11	baricitinib	baricitinib	NNP
cord-275349-b35pt3mo	24	12	therapy	therapy	NN
cord-275349-b35pt3mo	24	13	was	be	VBD
cord-275349-b35pt3mo	24	14	also	also	RB
cord-275349-b35pt3mo	24	15	associated	associate	VBN
cord-275349-b35pt3mo	24	16	with	with	IN
cord-275349-b35pt3mo	24	17	a	a	DT
cord-275349-b35pt3mo	24	18	reduction	reduction	NN
cord-275349-b35pt3mo	24	19	in	in	IN
cord-275349-b35pt3mo	24	20	the	the	DT
cord-275349-b35pt3mo	24	21	requirement	requirement	NN
cord-275349-b35pt3mo	24	22	for	for	IN
cord-275349-b35pt3mo	24	23	intensive	intensive	JJ
cord-275349-b35pt3mo	24	24	care	care	NN
cord-275349-b35pt3mo	24	25	unit	unit	NN
cord-275349-b35pt3mo	24	26	(	(	-LRB-
cord-275349-b35pt3mo	24	27	ICU	ICU	NNP
cord-275349-b35pt3mo	24	28	)	)	-RRB-
cord-275349-b35pt3mo	24	29	care	care	NN
cord-275349-b35pt3mo	24	30	when	when	WRB
cord-275349-b35pt3mo	24	31	compared	compare	VBN
cord-275349-b35pt3mo	24	32	with	with	IN
cord-275349-b35pt3mo	24	33	matched	match	VBN
cord-275349-b35pt3mo	24	34	case	case	NN
cord-275349-b35pt3mo	24	35	controls	control	NNS
cord-275349-b35pt3mo	24	36	[	[	-LRB-
cord-275349-b35pt3mo	24	37	6	6	CD
cord-275349-b35pt3mo	24	38	,	,	,
cord-275349-b35pt3mo	24	39	7	7	CD
cord-275349-b35pt3mo	24	40	]	]	-RRB-
cord-275349-b35pt3mo	24	41	.	.	.
cord-275349-b35pt3mo	25	1	In	in	IN
cord-275349-b35pt3mo	25	2	each	each	DT
cord-275349-b35pt3mo	25	3	series	series	NN
cord-275349-b35pt3mo	25	4	baricitinib	baricitinib	NN
cord-275349-b35pt3mo	25	5	treatment	treatment	NN
cord-275349-b35pt3mo	25	6	has	have	VBZ
cord-275349-b35pt3mo	25	7	been	be	VBN
cord-275349-b35pt3mo	25	8	associated	associate	VBN
cord-275349-b35pt3mo	25	9	with	with	IN
cord-275349-b35pt3mo	25	10	a	a	DT
cord-275349-b35pt3mo	25	11	reduction	reduction	NN
cord-275349-b35pt3mo	25	12	in	in	IN
cord-275349-b35pt3mo	25	13	inflammation	inflammation	NN
cord-275349-b35pt3mo	25	14	and	and	CC
cord-275349-b35pt3mo	25	15	recovery	recovery	NN
cord-275349-b35pt3mo	25	16	from	from	IN
cord-275349-b35pt3mo	25	17	the	the	DT
cord-275349-b35pt3mo	25	18	disease	disease	NN
cord-275349-b35pt3mo	25	19	in	in	IN
cord-275349-b35pt3mo	25	20	the	the	DT
cord-275349-b35pt3mo	25	21	vast	vast	JJ
cord-275349-b35pt3mo	25	22	majority	majority	NN
cord-275349-b35pt3mo	25	23	of	of	IN
cord-275349-b35pt3mo	25	24	patients	patient	NNS
cord-275349-b35pt3mo	25	25	,	,	,
cord-275349-b35pt3mo	25	26	consistent	consistent	JJ
cord-275349-b35pt3mo	25	27	with	with	IN
cord-275349-b35pt3mo	25	28	the	the	DT
cord-275349-b35pt3mo	25	29	present	present	JJ
cord-275349-b35pt3mo	25	30	report	report	NN
cord-275349-b35pt3mo	25	31	,	,	,
cord-275349-b35pt3mo	25	32	but	but	CC
cord-275349-b35pt3mo	25	33	we	-PRON-	PRP
cord-275349-b35pt3mo	25	34	do	do	VBP
cord-275349-b35pt3mo	25	35	not	not	RB
cord-275349-b35pt3mo	25	36	know	know	VB
cord-275349-b35pt3mo	25	37	if	if	IN
cord-275349-b35pt3mo	25	38	this	this	DT
cord-275349-b35pt3mo	25	39	is	be	VBZ
cord-275349-b35pt3mo	25	40	simply	simply	RB
cord-275349-b35pt3mo	25	41	an	an	DT
cord-275349-b35pt3mo	25	42	association	association	NN
cord-275349-b35pt3mo	25	43	or	or	CC
cord-275349-b35pt3mo	25	44	represents	represent	VBZ
cord-275349-b35pt3mo	25	45	a	a	DT
cord-275349-b35pt3mo	25	46	causative	causative	JJ
cord-275349-b35pt3mo	25	47	effect	effect	NN
cord-275349-b35pt3mo	25	48	of	of	IN
cord-275349-b35pt3mo	25	49	the	the	DT
cord-275349-b35pt3mo	25	50	drug	drug	NN
cord-275349-b35pt3mo	25	51	.	.	.
cord-275349-b35pt3mo	26	1	In	in	IN
cord-275349-b35pt3mo	26	2	this	this	DT
cord-275349-b35pt3mo	26	3	new	new	JJ
cord-275349-b35pt3mo	26	4	paper	paper	NN
cord-275349-b35pt3mo	26	5	,	,	,
cord-275349-b35pt3mo	26	6	3	3	CD
cord-275349-b35pt3mo	26	7	patients	patient	NNS
cord-275349-b35pt3mo	26	8	died	die	VBD
cord-275349-b35pt3mo	26	9	,	,	,
cord-275349-b35pt3mo	26	10	2	2	CD
cord-275349-b35pt3mo	26	11	of	of	IN
cord-275349-b35pt3mo	26	12	which	which	WDT
cord-275349-b35pt3mo	26	13	had	have	VBD
cord-275349-b35pt3mo	26	14	very	very	RB
cord-275349-b35pt3mo	26	15	high	high	JJ
cord-275349-b35pt3mo	26	16	plasma	plasma	NN
cord-275349-b35pt3mo	26	17	IL-6	IL-6	NNP
cord-275349-b35pt3mo	26	18	levels	level	NNS
cord-275349-b35pt3mo	26	19	prior	prior	RB
cord-275349-b35pt3mo	26	20	to	to	IN
cord-275349-b35pt3mo	26	21	starting	start	VBG
cord-275349-b35pt3mo	26	22	baricitinib	baricitinib	NNP
cord-275349-b35pt3mo	26	23	therapy	therapy	NN
cord-275349-b35pt3mo	26	24	consistent	consistent	JJ
cord-275349-b35pt3mo	26	25	with	with	IN
cord-275349-b35pt3mo	26	26	previous	previous	JJ
cord-275349-b35pt3mo	26	27	data	datum	NNS
cord-275349-b35pt3mo	26	28	that	that	WDT
cord-275349-b35pt3mo	26	29	high	high	JJ
cord-275349-b35pt3mo	26	30	IL-6	IL-6	NNP
cord-275349-b35pt3mo	26	31	is	be	VBZ
cord-275349-b35pt3mo	26	32	a	a	DT
cord-275349-b35pt3mo	26	33	predictor	predictor	NN
cord-275349-b35pt3mo	26	34	of	of	IN
cord-275349-b35pt3mo	26	35	mortality	mortality	NN
cord-275349-b35pt3mo	26	36	in	in	IN
cord-275349-b35pt3mo	26	37	COVD19	covd19	NN
cord-275349-b35pt3mo	26	38	infections	infection	NNS
cord-275349-b35pt3mo	26	39	[	[	-LRB-
cord-275349-b35pt3mo	26	40	8	8	CD
cord-275349-b35pt3mo	26	41	,	,	,
cord-275349-b35pt3mo	26	42	9	9	CD
cord-275349-b35pt3mo	26	43	]	]	-RRB-
cord-275349-b35pt3mo	26	44	.	.	.
cord-275349-b35pt3mo	27	1	These	these	DT
cord-275349-b35pt3mo	27	2	useful	useful	JJ
cord-275349-b35pt3mo	27	3	results	result	NNS
cord-275349-b35pt3mo	27	4	retrospectively	retrospectively	RB
cord-275349-b35pt3mo	27	5	justified	justify	VBD
cord-275349-b35pt3mo	27	6	the	the	DT
cord-275349-b35pt3mo	27	7	testing	testing	NN
cord-275349-b35pt3mo	27	8	of	of	IN
cord-275349-b35pt3mo	27	9	the	the	DT
cord-275349-b35pt3mo	27	10	anti	anti	JJ
cord-275349-b35pt3mo	27	11	-	-	NNP
cord-275349-b35pt3mo	27	12	IL6/	IL6/	NNP
cord-275349-b35pt3mo	27	13	IL6R	IL6R	NNP
cord-275349-b35pt3mo	27	14	antibodies	antibody	NNS
cord-275349-b35pt3mo	28	1	Kevzara	Kevzara	NNP
cord-275349-b35pt3mo	28	2	(	(	-LRB-
cord-275349-b35pt3mo	28	3	sarilumab	sarilumab	NNP
cord-275349-b35pt3mo	28	4	)	)	-RRB-
cord-275349-b35pt3mo	28	5	and	and	CC
cord-275349-b35pt3mo	28	6	Actemra	Actemra	NNP
cord-275349-b35pt3mo	28	7	(	(	-LRB-
cord-275349-b35pt3mo	28	8	tocilizumab	tocilizumab	NNP
cord-275349-b35pt3mo	28	9	)	)	-RRB-
cord-275349-b35pt3mo	28	10	in	in	IN
cord-275349-b35pt3mo	28	11	severely	severely	RB
cord-275349-b35pt3mo	28	12	unwell	unwell	JJ
cord-275349-b35pt3mo	28	13	patients	patient	NNS
cord-275349-b35pt3mo	28	14	,	,	,
cord-275349-b35pt3mo	28	15	although	although	IN
cord-275349-b35pt3mo	28	16	randomized	randomized	JJ
cord-275349-b35pt3mo	28	17	studies	study	NNS
cord-275349-b35pt3mo	28	18	are	be	VBP
cord-275349-b35pt3mo	28	19	yet	yet	RB
cord-275349-b35pt3mo	28	20	to	to	TO
cord-275349-b35pt3mo	28	21	show	show	VB
cord-275349-b35pt3mo	28	22	benefits	benefit	NNS
cord-275349-b35pt3mo	28	23	.	.	.
cord-275349-b35pt3mo	29	1	Baricitinib	Baricitinib	NNP
cord-275349-b35pt3mo	29	2	treatment	treatment	NN
cord-275349-b35pt3mo	29	3	over	over	IN
cord-275349-b35pt3mo	29	4	prolonged	prolong	VBN
cord-275349-b35pt3mo	29	5	periods	period	NNS
cord-275349-b35pt3mo	29	6	in	in	IN
cord-275349-b35pt3mo	29	7	RA	RA	NNP
cord-275349-b35pt3mo	29	8	patients	patient	NNS
cord-275349-b35pt3mo	29	9	has	have	VBZ
cord-275349-b35pt3mo	29	10	been	be	VBN
cord-275349-b35pt3mo	29	11	associated	associate	VBN
cord-275349-b35pt3mo	29	12	with	with	IN
cord-275349-b35pt3mo	29	13	increased	increase	VBN
cord-275349-b35pt3mo	29	14	infections	infection	NNS
cord-275349-b35pt3mo	29	15	and	and	CC
cord-275349-b35pt3mo	29	16	thromboembolism	thromboembolism	NN
cord-275349-b35pt3mo	29	17	,	,	,
cord-275349-b35pt3mo	29	18	but	but	CC
cord-275349-b35pt3mo	29	19	the	the	DT
cord-275349-b35pt3mo	29	20	short	short	JJ
cord-275349-b35pt3mo	29	21	duration	duration	NN
cord-275349-b35pt3mo	29	22	of	of	IN
cord-275349-b35pt3mo	29	23	treatment	treatment	NN
cord-275349-b35pt3mo	29	24	in	in	IN
cord-275349-b35pt3mo	29	25	COVID-19	covid-19	CD
cord-275349-b35pt3mo	29	26	patients	patient	NNS
cord-275349-b35pt3mo	29	27	may	may	MD
cord-275349-b35pt3mo	29	28	mitigate	mitigate	VB
cord-275349-b35pt3mo	29	29	against	against	IN
cord-275349-b35pt3mo	29	30	such	such	JJ
cord-275349-b35pt3mo	29	31	side	side	NN
cord-275349-b35pt3mo	29	32	effects	effect	NNS
cord-275349-b35pt3mo	29	33	.	.	.
cord-275349-b35pt3mo	30	1	In	in	IN
cord-275349-b35pt3mo	30	2	this	this	DT
cord-275349-b35pt3mo	30	3	report	report	NN
cord-275349-b35pt3mo	30	4	it	-PRON-	PRP
cord-275349-b35pt3mo	30	5	is	be	VBZ
cord-275349-b35pt3mo	30	6	difficult	difficult	JJ
cord-275349-b35pt3mo	30	7	to	to	TO
cord-275349-b35pt3mo	30	8	say	say	VB
cord-275349-b35pt3mo	30	9	whether	whether	IN
cord-275349-b35pt3mo	30	10	one	one	CD
cord-275349-b35pt3mo	30	11	incident	incident	NN
cord-275349-b35pt3mo	30	12	of	of	IN
cord-275349-b35pt3mo	30	13	pulmonary	pulmonary	JJ
cord-275349-b35pt3mo	30	14	embolism	embolism	NN
cord-275349-b35pt3mo	30	15	and	and	CC
cord-275349-b35pt3mo	30	16	methicillinresistant	methicillinresistant	JJ
cord-275349-b35pt3mo	30	17	Staphylococcus	Staphylococcus	NNP
cord-275349-b35pt3mo	30	18	aureus	aureus	NN
cord-275349-b35pt3mo	30	19	(	(	-LRB-
cord-275349-b35pt3mo	30	20	MRSA	MRSA	NNP
cord-275349-b35pt3mo	30	21	)	)	-RRB-
cord-275349-b35pt3mo	30	22	infection	infection	NN
cord-275349-b35pt3mo	30	23	were	be	VBD
cord-275349-b35pt3mo	30	24	due	due	JJ
cord-275349-b35pt3mo	30	25	to	to	IN
cord-275349-b35pt3mo	30	26	the	the	DT
cord-275349-b35pt3mo	30	27	complications	complication	NNS
cord-275349-b35pt3mo	30	28	of	of	IN
cord-275349-b35pt3mo	30	29	COVID-19	covid-19	CD
cord-275349-b35pt3mo	30	30	or	or	CC
cord-275349-b35pt3mo	30	31	baricitinib	baricitinib	NNP
cord-275349-b35pt3mo	30	32	,	,	,
cord-275349-b35pt3mo	30	33	but	but	CC
cord-275349-b35pt3mo	30	34	the	the	DT
cord-275349-b35pt3mo	30	35	much	much	RB
cord-275349-b35pt3mo	30	36	larger	large	JJR
cord-275349-b35pt3mo	30	37	numbers	number	NNS
cord-275349-b35pt3mo	30	38	of	of	IN
cord-275349-b35pt3mo	30	39	patients	patient	NNS
cord-275349-b35pt3mo	30	40	in	in	IN
cord-275349-b35pt3mo	30	41	the	the	DT
cord-275349-b35pt3mo	30	42	yet	yet	RB
cord-275349-b35pt3mo	30	43	to	to	TO
cord-275349-b35pt3mo	30	44	report	report	VB
cord-275349-b35pt3mo	30	45	randomized	randomized	JJ
cord-275349-b35pt3mo	30	46	studies	study	NNS
cord-275349-b35pt3mo	30	47	should	should	MD
cord-275349-b35pt3mo	30	48	clarify	clarify	VB
cord-275349-b35pt3mo	30	49	this	this	DT
cord-275349-b35pt3mo	30	50	.	.	.
cord-275349-b35pt3mo	31	1	One	one	PRP
cord-275349-b35pt3mo	31	2	would	would	MD
cord-275349-b35pt3mo	31	3	be	be	VB
cord-275349-b35pt3mo	31	4	advised	advise	VBN
cord-275349-b35pt3mo	31	5	to	to	TO
cord-275349-b35pt3mo	31	6	remain	remain	VB
cord-275349-b35pt3mo	31	7	vigilant	vigilant	JJ
cord-275349-b35pt3mo	31	8	of	of	IN
cord-275349-b35pt3mo	31	9	such	such	JJ
cord-275349-b35pt3mo	31	10	signals	signal	NNS
cord-275349-b35pt3mo	31	11	reflecting	reflect	VBG
cord-275349-b35pt3mo	31	12	thromboembolic	thromboembolic	NN
cord-275349-b35pt3mo	31	13	or	or	CC
cord-275349-b35pt3mo	31	14	infection	infection	NN
cord-275349-b35pt3mo	31	15	risk	risk	NN
cord-275349-b35pt3mo	31	16	in	in	IN
cord-275349-b35pt3mo	31	17	randomized	randomized	JJ
cord-275349-b35pt3mo	31	18	controlled	controlled	JJ
cord-275349-b35pt3mo	31	19	trials	trial	NNS
cord-275349-b35pt3mo	31	20	testing	test	VBG
cord-275349-b35pt3mo	31	21	a	a	DT
cord-275349-b35pt3mo	31	22	variety	variety	NN
cord-275349-b35pt3mo	31	23	of	of	IN
cord-275349-b35pt3mo	31	24	immunomodulatory	immunomodulatory	JJ
cord-275349-b35pt3mo	31	25	therapies	therapy	NNS
cord-275349-b35pt3mo	31	26	in	in	IN
cord-275349-b35pt3mo	31	27	COVID-19	COVID-19	NNP
cord-275349-b35pt3mo	31	28	patients	patient	NNS
cord-275349-b35pt3mo	31	29	,	,	,
cord-275349-b35pt3mo	31	30	either	either	CC
cord-275349-b35pt3mo	31	31	alone	alone	RB
cord-275349-b35pt3mo	31	32	or	or	CC
cord-275349-b35pt3mo	31	33	in	in	IN
cord-275349-b35pt3mo	31	34	combination	combination	NN
cord-275349-b35pt3mo	31	35	,	,	,
cord-275349-b35pt3mo	31	36	especially	especially	RB
cord-275349-b35pt3mo	31	37	in	in	IN
cord-275349-b35pt3mo	31	38	view	view	NN
cord-275349-b35pt3mo	31	39	of	of	IN
cord-275349-b35pt3mo	31	40	associations	association	NNS
cord-275349-b35pt3mo	31	41	between	between	IN
cord-275349-b35pt3mo	31	42	clots	clot	NNS
cord-275349-b35pt3mo	31	43	and	and	CC
cord-275349-b35pt3mo	31	44	SARS	SARS	NNP
cord-275349-b35pt3mo	31	45	-	-	HYPH
cord-275349-b35pt3mo	31	46	CoV-2	CoV-2	NNP
cord-275349-b35pt3mo	31	47	infection	infection	NN
cord-275349-b35pt3mo	31	48	[	[	-LRB-
cord-275349-b35pt3mo	31	49	10	10	CD
cord-275349-b35pt3mo	31	50	]	]	-RRB-
cord-275349-b35pt3mo	31	51	.	.	.
cord-275349-b35pt3mo	32	1	Specifically	specifically	RB
cord-275349-b35pt3mo	32	2	,	,	,
cord-275349-b35pt3mo	32	3	severe	severe	JJ
cord-275349-b35pt3mo	32	4	endothelial	endothelial	JJ
cord-275349-b35pt3mo	32	5	injury	injury	NN
cord-275349-b35pt3mo	32	6	associated	associate	VBN
cord-275349-b35pt3mo	32	7	with	with	IN
cord-275349-b35pt3mo	32	8	intracellular	intracellular	JJ
cord-275349-b35pt3mo	32	9	SARS	SARS	NNP
cord-275349-b35pt3mo	32	10	-	-	HYPH
cord-275349-b35pt3mo	32	11	CoV-2	CoV-2	NNP
cord-275349-b35pt3mo	32	12	virus	virus	NN
cord-275349-b35pt3mo	32	13	and	and	CC
cord-275349-b35pt3mo	32	14	disrupted	disrupt	VBD
cord-275349-b35pt3mo	32	15	endothelial	endothelial	JJ
cord-275349-b35pt3mo	32	16	cell	cell	NN
cord-275349-b35pt3mo	32	17	membranes	membrane	NNS
cord-275349-b35pt3mo	32	18	,	,	,
cord-275349-b35pt3mo	32	19	widespread	widespread	JJ
cord-275349-b35pt3mo	32	20	vascular	vascular	JJ
cord-275349-b35pt3mo	32	21	thrombosis	thrombosis	NN
cord-275349-b35pt3mo	32	22	with	with	IN
cord-275349-b35pt3mo	32	23	microangiopathy	microangiopathy	NNP
cord-275349-b35pt3mo	32	24	,	,	,
cord-275349-b35pt3mo	32	25	and	and	CC
cord-275349-b35pt3mo	32	26	occlusion	occlusion	NN
cord-275349-b35pt3mo	32	27	of	of	IN
cord-275349-b35pt3mo	32	28	alveolar	alveolar	JJ
cord-275349-b35pt3mo	32	29	capillaries	capillary	NNS
cord-275349-b35pt3mo	32	30	including	include	VBG
cord-275349-b35pt3mo	32	31	significant	significant	JJ
cord-275349-b35pt3mo	32	32	new	new	JJ
cord-275349-b35pt3mo	32	33	vessel	vessel	NN
cord-275349-b35pt3mo	32	34	growth	growth	NN
cord-275349-b35pt3mo	32	35	through	through	IN
cord-275349-b35pt3mo	32	36	a	a	DT
cord-275349-b35pt3mo	32	37	mechanism	mechanism	NN
cord-275349-b35pt3mo	32	38	of	of	IN
cord-275349-b35pt3mo	32	39	intussusceptive	intussusceptive	JJ
cord-275349-b35pt3mo	32	40	angiogenesis	angiogenesis	NN
cord-275349-b35pt3mo	32	41	has	have	VBZ
cord-275349-b35pt3mo	32	42	been	be	VBN
cord-275349-b35pt3mo	32	43	described	describe	VBN
cord-275349-b35pt3mo	32	44	[	[	-LRB-
cord-275349-b35pt3mo	32	45	11	11	CD
cord-275349-b35pt3mo	32	46	]	]	-RRB-
cord-275349-b35pt3mo	32	47	.	.	.
cord-275349-b35pt3mo	33	1	The	the	DT
cord-275349-b35pt3mo	33	2	first	first	JJ
cord-275349-b35pt3mo	33	3	report	report	NN
cord-275349-b35pt3mo	33	4	of	of	IN
cord-275349-b35pt3mo	33	5	a	a	DT
cord-275349-b35pt3mo	33	6	significant	significant	JJ
cord-275349-b35pt3mo	33	7	reduction	reduction	NN
cord-275349-b35pt3mo	33	8	in	in	IN
cord-275349-b35pt3mo	33	9	COVID-19	COVID-19	NNP
cord-275349-b35pt3mo	33	10	mortality	mortality	NN
cord-275349-b35pt3mo	33	11	in	in	IN
cord-275349-b35pt3mo	33	12	any	any	DT
cord-275349-b35pt3mo	33	13	randomized	randomized	JJ
cord-275349-b35pt3mo	33	14	study	study	NN
cord-275349-b35pt3mo	33	15	recently	recently	RB
cord-275349-b35pt3mo	33	16	came	come	VBD
cord-275349-b35pt3mo	33	17	from	from	IN
cord-275349-b35pt3mo	33	18	the	the	DT
cord-275349-b35pt3mo	33	19	RECOVERY	recovery	NN
cord-275349-b35pt3mo	33	20	trial	trial	NN
cord-275349-b35pt3mo	33	21	in	in	IN
cord-275349-b35pt3mo	33	22	the	the	DT
cord-275349-b35pt3mo	33	23	United	United	NNP
cord-275349-b35pt3mo	33	24	Kingdom	Kingdom	NNP
cord-275349-b35pt3mo	33	25	showing	show	VBG
cord-275349-b35pt3mo	33	26	that	that	DT
cord-275349-b35pt3mo	33	27	low	low	JJ
cord-275349-b35pt3mo	33	28	dose	dose	NN
cord-275349-b35pt3mo	33	29	dexamethasone	dexamethasone	NN
cord-275349-b35pt3mo	33	30	had	have	VBD
cord-275349-b35pt3mo	33	31	a	a	DT
cord-275349-b35pt3mo	33	32	significant	significant	JJ
cord-275349-b35pt3mo	33	33	effect	effect	NN
cord-275349-b35pt3mo	33	34	in	in	IN
cord-275349-b35pt3mo	33	35	reducing	reduce	VBG
cord-275349-b35pt3mo	33	36	mortality	mortality	NN
cord-275349-b35pt3mo	33	37	when	when	WRB
cord-275349-b35pt3mo	33	38	given	give	VBN
cord-275349-b35pt3mo	33	39	with	with	IN
cord-275349-b35pt3mo	33	40	standard	standard	NN
cord-275349-b35pt3mo	33	41	of	of	IN
cord-275349-b35pt3mo	33	42	care	care	NN
cord-275349-b35pt3mo	33	43	(	(	-LRB-
cord-275349-b35pt3mo	33	44	21.6	21.6	CD
cord-275349-b35pt3mo	33	45	%	%	NN
cord-275349-b35pt3mo	33	46	vs	vs	IN
cord-275349-b35pt3mo	33	47	24.6	24.6	CD
cord-275349-b35pt3mo	33	48	%	%	NN
cord-275349-b35pt3mo	33	49	of	of	IN
cord-275349-b35pt3mo	33	50	the	the	DT
cord-275349-b35pt3mo	33	51	patients	patient	NNS
cord-275349-b35pt3mo	33	52	dying	die	VBG
cord-275349-b35pt3mo	33	53	within	within	IN
cord-275349-b35pt3mo	33	54	28	28	CD
cord-275349-b35pt3mo	33	55	days	day	NNS
cord-275349-b35pt3mo	33	56	)	)	-RRB-
cord-275349-b35pt3mo	34	1	[	[	-LRB-
cord-275349-b35pt3mo	34	2	12	12	CD
cord-275349-b35pt3mo	34	3	]	]	-RRB-
cord-275349-b35pt3mo	34	4	;	;	:
cord-275349-b35pt3mo	34	5	this	this	DT
cord-275349-b35pt3mo	34	6	effect	effect	NN
cord-275349-b35pt3mo	34	7	was	be	VBD
cord-275349-b35pt3mo	34	8	greatest	great	JJS
cord-275349-b35pt3mo	34	9	in	in	IN
cord-275349-b35pt3mo	34	10	ventilated	ventilate	VBN
cord-275349-b35pt3mo	34	11	patients	patient	NNS
cord-275349-b35pt3mo	34	12	(	(	-LRB-
cord-275349-b35pt3mo	34	13	a	a	DT
cord-275349-b35pt3mo	34	14	30	30	CD
cord-275349-b35pt3mo	34	15	%	%	NN
cord-275349-b35pt3mo	34	16	reduction	reduction	NN
cord-275349-b35pt3mo	34	17	in	in	IN
cord-275349-b35pt3mo	34	18	mortality	mortality	NN
cord-275349-b35pt3mo	34	19	)	)	-RRB-
cord-275349-b35pt3mo	34	20	and	and	CC
cord-275349-b35pt3mo	34	21	slightly	slightly	RB
cord-275349-b35pt3mo	34	22	less	less	JJR
cord-275349-b35pt3mo	34	23	in	in	IN
cord-275349-b35pt3mo	34	24	those	those	DT
cord-275349-b35pt3mo	34	25	provided	provide	VBN
cord-275349-b35pt3mo	34	26	with	with	IN
cord-275349-b35pt3mo	34	27	noninvasive	noninvasive	JJ
cord-275349-b35pt3mo	34	28	supplemental	supplemental	JJ
cord-275349-b35pt3mo	34	29	oxygen	oxygen	NN
cord-275349-b35pt3mo	34	30	(	(	-LRB-
cord-275349-b35pt3mo	34	31	a	a	DT
cord-275349-b35pt3mo	34	32	20	20	CD
cord-275349-b35pt3mo	34	33	%	%	NN
cord-275349-b35pt3mo	34	34	reduction	reduction	NN
cord-275349-b35pt3mo	34	35	)	)	-RRB-
cord-275349-b35pt3mo	35	1	[	[	-LRB-
cord-275349-b35pt3mo	35	2	12	12	CD
cord-275349-b35pt3mo	35	3	]	]	-RRB-
cord-275349-b35pt3mo	35	4	.	.	.
cord-275349-b35pt3mo	36	1	It	-PRON-	PRP
cord-275349-b35pt3mo	36	2	is	be	VBZ
cord-275349-b35pt3mo	36	3	tempting	tempt	VBG
cord-275349-b35pt3mo	36	4	to	to	TO
cord-275349-b35pt3mo	36	5	speculate	speculate	VB
cord-275349-b35pt3mo	36	6	that	that	IN
cord-275349-b35pt3mo	36	7	a	a	DT
cord-275349-b35pt3mo	36	8	similar	similar	JJ
cord-275349-b35pt3mo	36	9	or	or	CC
cord-275349-b35pt3mo	36	10	greater	great	JJR
cord-275349-b35pt3mo	36	11	reduction	reduction	NN
cord-275349-b35pt3mo	36	12	in	in	IN
cord-275349-b35pt3mo	36	13	mortality	mortality	NN
cord-275349-b35pt3mo	36	14	could	could	MD
cord-275349-b35pt3mo	36	15	be	be	VB
cord-275349-b35pt3mo	36	16	expected	expect	VBN
cord-275349-b35pt3mo	36	17	with	with	IN
cord-275349-b35pt3mo	36	18	baricitinib	baricitinib	NN
cord-275349-b35pt3mo	36	19	in	in	IN
cord-275349-b35pt3mo	36	20	randomized	randomized	JJ
cord-275349-b35pt3mo	36	21	trials	trial	NNS
cord-275349-b35pt3mo	36	22	,	,	,
cord-275349-b35pt3mo	36	23	especially	especially	RB
cord-275349-b35pt3mo	36	24	because	because	IN
cord-275349-b35pt3mo	36	25	baricitinib	baricitinib	NNP
cord-275349-b35pt3mo	36	26	is	be	VBZ
cord-275349-b35pt3mo	36	27	now	now	RB
cord-275349-b35pt3mo	36	28	reported	report	VBN
cord-275349-b35pt3mo	36	29	to	to	TO
cord-275349-b35pt3mo	36	30	be	be	VB
cord-275349-b35pt3mo	36	31	associated	associate	VBN
cord-275349-b35pt3mo	36	32	with	with	IN
cord-275349-b35pt3mo	36	33	recovery	recovery	NN
cord-275349-b35pt3mo	36	34	from	from	IN
cord-275349-b35pt3mo	36	35	COVID-19	COVID-19	NNP
cord-275349-b35pt3mo	36	36	in	in	IN
cord-275349-b35pt3mo	36	37	different	different	JJ
cord-275349-b35pt3mo	36	38	series	series	NN
cord-275349-b35pt3mo	36	39	of	of	IN
cord-275349-b35pt3mo	36	40	patients	patient	NNS
cord-275349-b35pt3mo	36	41	.	.	.
cord-275349-b35pt3mo	37	1	It	-PRON-	PRP
cord-275349-b35pt3mo	37	2	may	may	MD
cord-275349-b35pt3mo	37	3	even	even	RB
cord-275349-b35pt3mo	37	4	be	be	VB
cord-275349-b35pt3mo	37	5	possible	possible	JJ
cord-275349-b35pt3mo	37	6	to	to	TO
cord-275349-b35pt3mo	37	7	combine	combine	VB
cord-275349-b35pt3mo	37	8	the	the	DT
cord-275349-b35pt3mo	37	9	baricitinib	baricitinib	NN
cord-275349-b35pt3mo	37	10	with	with	IN
cord-275349-b35pt3mo	37	11	dexamethasone	dexamethasone	NN
cord-275349-b35pt3mo	37	12	,	,	,
cord-275349-b35pt3mo	37	13	at	at	IN
cord-275349-b35pt3mo	37	14	least	least	JJS
cord-275349-b35pt3mo	37	15	in	in	IN
cord-275349-b35pt3mo	37	16	critically	critically	RB
cord-275349-b35pt3mo	37	17	ill	ill	JJ
cord-275349-b35pt3mo	37	18	patients	patient	NNS
cord-275349-b35pt3mo	37	19	,	,	,
cord-275349-b35pt3mo	37	20	although	although	IN
cord-275349-b35pt3mo	37	21	once	once	RB
cord-275349-b35pt3mo	37	22	again	again	RB
cord-275349-b35pt3mo	37	23	it	-PRON-	PRP
cord-275349-b35pt3mo	37	24	would	would	MD
cord-275349-b35pt3mo	37	25	of	of	IN
cord-275349-b35pt3mo	37	26	course	course	NN
cord-275349-b35pt3mo	37	27	be	be	VB
cord-275349-b35pt3mo	37	28	important	important	JJ
cord-275349-b35pt3mo	37	29	to	to	TO
cord-275349-b35pt3mo	37	30	assess	assess	VB
cord-275349-b35pt3mo	37	31	the	the	DT
cord-275349-b35pt3mo	37	32	risk	risk	NN
cord-275349-b35pt3mo	37	33	of	of	IN
cord-275349-b35pt3mo	37	34	infection	infection	NN
cord-275349-b35pt3mo	37	35	when	when	WRB
cord-275349-b35pt3mo	37	36	administering	administer	VBG
cord-275349-b35pt3mo	37	37	these	these	DT
cord-275349-b35pt3mo	37	38	2	2	CD
cord-275349-b35pt3mo	37	39	potent	potent	JJ
cord-275349-b35pt3mo	37	40	anti	anti	JJ
cord-275349-b35pt3mo	37	41	-	-	JJ
cord-275349-b35pt3mo	37	42	inflammatory	inflammatory	JJ
cord-275349-b35pt3mo	37	43	agents	agent	NNS
cord-275349-b35pt3mo	37	44	together	together	RB
cord-275349-b35pt3mo	37	45	.	.	.
cord-275349-b35pt3mo	38	1	As	as	IN
cord-275349-b35pt3mo	38	2	acknowledged	acknowledge	VBN
cord-275349-b35pt3mo	38	3	by	by	IN
cord-275349-b35pt3mo	38	4	Titanji	Titanji	NNP
cord-275349-b35pt3mo	38	5	et	et	NNP
cord-275349-b35pt3mo	38	6	al	al	NNP
cord-275349-b35pt3mo	38	7	,	,	,
cord-275349-b35pt3mo	38	8	and	and	CC
cord-275349-b35pt3mo	38	9	reiterated	reiterate	VBN
cord-275349-b35pt3mo	38	10	by	by	IN
cord-275349-b35pt3mo	38	11	us	-PRON-	PRP
cord-275349-b35pt3mo	38	12	,	,	,
cord-275349-b35pt3mo	38	13	randomized	randomized	JJ
cord-275349-b35pt3mo	38	14	trials	trial	NNS
cord-275349-b35pt3mo	38	15	are	be	VBP
cord-275349-b35pt3mo	38	16	required	require	VBN
cord-275349-b35pt3mo	38	17	for	for	IN
cord-275349-b35pt3mo	38	18	us	-PRON-	PRP
cord-275349-b35pt3mo	38	19	to	to	TO
cord-275349-b35pt3mo	38	20	be	be	VB
cord-275349-b35pt3mo	38	21	certain	certain	JJ
cord-275349-b35pt3mo	38	22	if	if	IN
cord-275349-b35pt3mo	38	23	baricitinib	baricitinib	NNP
cord-275349-b35pt3mo	38	24	is	be	VBZ
cord-275349-b35pt3mo	38	25	an	an	DT
cord-275349-b35pt3mo	38	26	effective	effective	JJ
cord-275349-b35pt3mo	38	27	and	and	CC
cord-275349-b35pt3mo	38	28	safe	safe	JJ
cord-275349-b35pt3mo	38	29	therapy	therapy	NN
cord-275349-b35pt3mo	38	30	for	for	IN
cord-275349-b35pt3mo	38	31	COVID-19	covid-19	JJ
cord-275349-b35pt3mo	38	32	patients	patient	NNS
cord-275349-b35pt3mo	38	33	[	[	-LRB-
cord-275349-b35pt3mo	38	34	3	3	CD
cord-275349-b35pt3mo	38	35	]	]	-RRB-
cord-275349-b35pt3mo	38	36	.	.	.
cord-275349-b35pt3mo	39	1	This	this	DT
cord-275349-b35pt3mo	39	2	report	report	NN
cord-275349-b35pt3mo	39	3	,	,	,
cord-275349-b35pt3mo	39	4	and	and	CC
cord-275349-b35pt3mo	39	5	others	other	NNS
cord-275349-b35pt3mo	39	6	like	like	IN
cord-275349-b35pt3mo	39	7	it	-PRON-	PRP
cord-275349-b35pt3mo	39	8	,	,	,
cord-275349-b35pt3mo	39	9	have	have	VBP
cord-275349-b35pt3mo	39	10	supported	support	VBN
cord-275349-b35pt3mo	39	11	the	the	DT
cord-275349-b35pt3mo	39	12	selection	selection	NN
cord-275349-b35pt3mo	39	13	of	of	IN
cord-275349-b35pt3mo	39	14	baricitinib	baricitinib	NN
cord-275349-b35pt3mo	39	15	in	in	IN
cord-275349-b35pt3mo	39	16	a	a	DT
cord-275349-b35pt3mo	39	17	number	number	NN
cord-275349-b35pt3mo	39	18	of	of	IN
cord-275349-b35pt3mo	39	19	studies	study	NNS
cord-275349-b35pt3mo	39	20	including	include	VBG
cord-275349-b35pt3mo	39	21	the	the	DT
cord-275349-b35pt3mo	39	22	ACTT2	actt2	RB
cord-275349-b35pt3mo	39	23	randomized	randomized	JJ
cord-275349-b35pt3mo	39	24	trial	trial	NN
cord-275349-b35pt3mo	39	25	,	,	,
cord-275349-b35pt3mo	39	26	where	where	WRB
cord-275349-b35pt3mo	39	27	it	-PRON-	PRP
cord-275349-b35pt3mo	39	28	is	be	VBZ
cord-275349-b35pt3mo	39	29	being	be	VBG
cord-275349-b35pt3mo	39	30	tested	test	VBN
cord-275349-b35pt3mo	39	31	in	in	IN
cord-275349-b35pt3mo	39	32	combination	combination	NN
cord-275349-b35pt3mo	39	33	with	with	IN
cord-275349-b35pt3mo	39	34	remdesivir	remdesivir	NNP
cord-275349-b35pt3mo	39	35	,	,	,
cord-275349-b35pt3mo	39	36	and	and	CC
cord-275349-b35pt3mo	39	37	a	a	DT
cord-275349-b35pt3mo	39	38	further	further	JJ
cord-275349-b35pt3mo	39	39	placebocontrolled	placebocontrolled	JJ
cord-275349-b35pt3mo	39	40	phase	phase	NN
cord-275349-b35pt3mo	39	41	3	3	CD
cord-275349-b35pt3mo	39	42	trial	trial	NN
cord-275349-b35pt3mo	39	43	recently	recently	RB
cord-275349-b35pt3mo	39	44	commenced	commence	VBD
cord-275349-b35pt3mo	39	45	.	.	.
cord-275349-b35pt3mo	40	1	It	-PRON-	PRP
cord-275349-b35pt3mo	40	2	is	be	VBZ
cord-275349-b35pt3mo	40	3	anticipated	anticipate	VBN
cord-275349-b35pt3mo	40	4	that	that	IN
cord-275349-b35pt3mo	40	5	these	these	DT
cord-275349-b35pt3mo	40	6	trials	trial	NNS
cord-275349-b35pt3mo	40	7	should	should	MD
cord-275349-b35pt3mo	40	8	provide	provide	VB
cord-275349-b35pt3mo	40	9	a	a	DT
cord-275349-b35pt3mo	40	10	robust	robust	JJ
cord-275349-b35pt3mo	40	11	estimate	estimate	NN
cord-275349-b35pt3mo	40	12	of	of	IN
cord-275349-b35pt3mo	40	13	the	the	DT
cord-275349-b35pt3mo	40	14	efficacy	efficacy	NN
cord-275349-b35pt3mo	40	15	of	of	IN
cord-275349-b35pt3mo	40	16	baricitinib	baricitinib	NNP
cord-275349-b35pt3mo	40	17	in	in	IN
cord-275349-b35pt3mo	40	18	COVID-19	COVID-19	NNP
cord-275349-b35pt3mo	40	19	and	and	CC
cord-275349-b35pt3mo	40	20	would	would	MD
cord-275349-b35pt3mo	40	21	be	be	VB
cord-275349-b35pt3mo	40	22	complementary	complementary	JJ
cord-275349-b35pt3mo	40	23	to	to	IN
cord-275349-b35pt3mo	40	24	each	each	DT
cord-275349-b35pt3mo	40	25	other	other	JJ
cord-275349-b35pt3mo	40	26	.	.	.
cord-275349-b35pt3mo	41	1	These	these	DT
cord-275349-b35pt3mo	41	2	initial	initial	JJ
cord-275349-b35pt3mo	41	3	case	case	NN
cord-275349-b35pt3mo	41	4	series	series	NN
cord-275349-b35pt3mo	41	5	warrant	warrant	VBP
cord-275349-b35pt3mo	41	6	further	further	JJ
cord-275349-b35pt3mo	41	7	confirmation	confirmation	NN
cord-275349-b35pt3mo	41	8	from	from	IN
cord-275349-b35pt3mo	41	9	the	the	DT
cord-275349-b35pt3mo	41	10	ongoing	ongoing	JJ
cord-275349-b35pt3mo	41	11	larger	large	JJR
cord-275349-b35pt3mo	41	12	,	,	,
cord-275349-b35pt3mo	41	13	randomized	randomized	JJ
cord-275349-b35pt3mo	41	14	and	and	CC
cord-275349-b35pt3mo	41	15	controlled	control	VBN
cord-275349-b35pt3mo	41	16	trials	trial	NNS
cord-275349-b35pt3mo	41	17	.	.	.
cord-275349-b35pt3mo	42	1	Thus	thus	RB
cord-275349-b35pt3mo	42	2	far	far	RB
cord-275349-b35pt3mo	42	3	,	,	,
cord-275349-b35pt3mo	42	4	these	these	DT
cord-275349-b35pt3mo	42	5	data	datum	NNS
cord-275349-b35pt3mo	42	6	sets	set	NNS
cord-275349-b35pt3mo	42	7	also	also	RB
cord-275349-b35pt3mo	42	8	validate	validate	VBP
cord-275349-b35pt3mo	42	9	use	use	NN
cord-275349-b35pt3mo	42	10	of	of	IN
cord-275349-b35pt3mo	42	11	artificial	artificial	JJ
cord-275349-b35pt3mo	42	12	intelligence	intelligence	NN
cord-275349-b35pt3mo	42	13	at	at	IN
cord-275349-b35pt3mo	42	14	a	a	DT
cord-275349-b35pt3mo	42	15	time	time	NN
cord-275349-b35pt3mo	42	16	of	of	IN
cord-275349-b35pt3mo	42	17	a	a	DT
cord-275349-b35pt3mo	42	18	biomedical	biomedical	JJ
cord-275349-b35pt3mo	42	19	crisis	crisis	NN
cord-275349-b35pt3mo	42	20	,	,	,
cord-275349-b35pt3mo	42	21	to	to	TO
cord-275349-b35pt3mo	42	22	help	help	VB
cord-275349-b35pt3mo	42	23	speed	speed	VB
cord-275349-b35pt3mo	42	24	drug	drug	NN
cord-275349-b35pt3mo	42	25	development	development	NN
cord-275349-b35pt3mo	42	26	.	.	.
cord-275349-b35pt3mo	43	1	The	the	DT
cord-275349-b35pt3mo	43	2	use	use	NN
cord-275349-b35pt3mo	43	3	of	of	IN
cord-275349-b35pt3mo	43	4	an	an	DT
cord-275349-b35pt3mo	43	5	oral	oral	JJ
cord-275349-b35pt3mo	43	6	medicine	medicine	NN
cord-275349-b35pt3mo	43	7	taken	take	VBN
cord-275349-b35pt3mo	43	8	once	once	RB
cord-275349-b35pt3mo	43	9	daily	daily	RB
cord-275349-b35pt3mo	43	10	for	for	IN
cord-275349-b35pt3mo	43	11	a	a	DT
cord-275349-b35pt3mo	43	12	short	short	JJ
cord-275349-b35pt3mo	43	13	duration	duration	NN
cord-275349-b35pt3mo	43	14	should	should	MD
cord-275349-b35pt3mo	43	15	also	also	RB
cord-275349-b35pt3mo	43	16	lend	lend	VB
cord-275349-b35pt3mo	43	17	itself	-PRON-	PRP
cord-275349-b35pt3mo	43	18	to	to	IN
cord-275349-b35pt3mo	43	19	low	low	JJ
cord-275349-b35pt3mo	43	20	-	-	HYPH
cord-275349-b35pt3mo	43	21	and	and	CC
cord-275349-b35pt3mo	43	22	middle	middle	JJ
cord-275349-b35pt3mo	43	23	-	-	HYPH
cord-275349-b35pt3mo	43	24	income	income	NN
cord-275349-b35pt3mo	43	25	countries	country	NNS
cord-275349-b35pt3mo	43	26	.	.	.
cord-275349-b35pt3mo	44	1	Note	note	VB
cord-275349-b35pt3mo	44	2	Potential	potential	JJ
cord-275349-b35pt3mo	44	3	conflicts	conflict	NNS
cord-275349-b35pt3mo	44	4	of	of	IN
cord-275349-b35pt3mo	44	5	interest	interest	NN
cord-275349-b35pt3mo	44	6	.	.	.
cord-275349-b35pt3mo	45	1	P.	P.	NNP
cord-275349-b35pt3mo	45	2	J.	J.	NNP
cord-275349-b35pt3mo	45	3	R.	R.	NNP
cord-275349-b35pt3mo	45	4	is	be	VBZ
cord-275349-b35pt3mo	45	5	an	an	DT
cord-275349-b35pt3mo	45	6	employee	employee	NN
cord-275349-b35pt3mo	45	7	of	of	IN
cord-275349-b35pt3mo	45	8	BenevolentAI	benevolentai	NN
cord-275349-b35pt3mo	45	9	and	and	CC
cord-275349-b35pt3mo	45	10	has	have	VBZ
cord-275349-b35pt3mo	45	11	received	receive	VBN
cord-275349-b35pt3mo	45	12	honoraria	honorarium	NNS
cord-275349-b35pt3mo	45	13	for	for	IN
cord-275349-b35pt3mo	45	14	giving	give	VBG
cord-275349-b35pt3mo	45	15	a	a	DT
cord-275349-b35pt3mo	45	16	lecture	lecture	NN
cord-275349-b35pt3mo	45	17	to	to	IN
cord-275349-b35pt3mo	45	18	Lilly	Lilly	NNP
cord-275349-b35pt3mo	45	19	with	with	IN
cord-275349-b35pt3mo	45	20	J.	J.	NNP
cord-275349-b35pt3mo	45	21	S.	S.	NNP
cord-275349-b35pt3mo	46	1	And	and	CC
cord-275349-b35pt3mo	46	2	J.	J.	NNP
cord-275349-b35pt3mo	46	3	S.	S.	NNP
cord-275349-b35pt3mo	46	4	has	have	VBZ
cord-275349-b35pt3mo	46	5	sat	sit	VBN
cord-275349-b35pt3mo	46	6	on	on	IN
cord-275349-b35pt3mo	46	7	SABs	sab	NNS
cord-275349-b35pt3mo	46	8	for	for	IN
cord-275349-b35pt3mo	46	9	Vaccitech	Vaccitech	NNP
cord-275349-b35pt3mo	46	10	,	,	,
cord-275349-b35pt3mo	46	11	Heat	Heat	NNP
cord-275349-b35pt3mo	46	12	Biologics	Biologics	NNPS
cord-275349-b35pt3mo	46	13	,	,	,
cord-275349-b35pt3mo	46	14	Eli	Eli	NNP
cord-275349-b35pt3mo	46	15	Lilly	Lilly	NNP
cord-275349-b35pt3mo	46	16	,	,	,
cord-275349-b35pt3mo	46	17	Replete	replete	JJ
cord-275349-b35pt3mo	46	18	,	,	,
cord-275349-b35pt3mo	46	19	Alveo	Alveo	NNP
cord-275349-b35pt3mo	46	20	,	,	,
cord-275349-b35pt3mo	46	21	Certis	Certis	NNP
cord-275349-b35pt3mo	46	22	Oncology	Oncology	NNP
cord-275349-b35pt3mo	46	23	Solutions	Solutions	NNPS
cord-275349-b35pt3mo	46	24	,	,	,
cord-275349-b35pt3mo	46	25	Greenmantle	Greenmantle	NNP
cord-275349-b35pt3mo	46	26	and	and	CC
cord-275349-b35pt3mo	46	27	BenevolentAI	benevolentai	NN
cord-275349-b35pt3mo	46	28	,	,	,
cord-275349-b35pt3mo	46	29	has	have	VBZ
cord-275349-b35pt3mo	46	30	consulted	consult	VBN
cord-275349-b35pt3mo	46	31	with	with	IN
cord-275349-b35pt3mo	46	32	Lansdowne	Lansdowne	NNP
cord-275349-b35pt3mo	46	33	partners	partner	NNS
cord-275349-b35pt3mo	46	34	and	and	CC
cord-275349-b35pt3mo	46	35	Vitruvian	vitruvian	JJ
cord-275349-b35pt3mo	46	36	.	.	.
cord-275349-b35pt3mo	47	1	He	-PRON-	PRP
cord-275349-b35pt3mo	47	2	sits	sit	VBZ
cord-275349-b35pt3mo	47	3	on	on	IN
cord-275349-b35pt3mo	47	4	the	the	DT
cord-275349-b35pt3mo	47	5	Board	Board	NNP
cord-275349-b35pt3mo	47	6	of	of	IN
cord-275349-b35pt3mo	47	7	Directors	Directors	NNPS
cord-275349-b35pt3mo	47	8	for	for	IN
cord-275349-b35pt3mo	47	9	BB	BB	NNP
cord-275349-b35pt3mo	47	10	Biotech	Biotech	NNP
cord-275349-b35pt3mo	47	11	Healthcare	Healthcare	NNP
cord-275349-b35pt3mo	47	12	Trust	Trust	NNP
cord-275349-b35pt3mo	47	13	.	.	.
cord-275349-b35pt3mo	48	1	H.-J.	H.-J.	NNP
cord-275349-b35pt3mo	49	1	L.	L.	NNP
cord-275349-b35pt3mo	49	2	has	have	VBZ
cord-275349-b35pt3mo	49	3	no	no	DT
cord-275349-b35pt3mo	49	4	reported	report	VBN
cord-275349-b35pt3mo	49	5	conflicts	conflict	NNS
cord-275349-b35pt3mo	49	6	.	.	.
cord-275349-b35pt3mo	50	1	All	all	DT
cord-275349-b35pt3mo	50	2	authors	author	NNS
cord-275349-b35pt3mo	50	3	have	have	VBP
cord-275349-b35pt3mo	50	4	submitted	submit	VBN
cord-275349-b35pt3mo	50	5	the	the	DT
cord-275349-b35pt3mo	50	6	ICMJE	ICMJE	NNP
cord-275349-b35pt3mo	50	7	Form	Form	NNP
cord-275349-b35pt3mo	50	8	for	for	IN
cord-275349-b35pt3mo	50	9	Disclosure	Disclosure	NNP
cord-275349-b35pt3mo	50	10	of	of	IN
cord-275349-b35pt3mo	50	11	Potential	potential	JJ
cord-275349-b35pt3mo	50	12	Conflicts	conflict	NNS
cord-275349-b35pt3mo	50	13	of	of	IN
cord-275349-b35pt3mo	50	14	Interest	interest	NN
cord-275349-b35pt3mo	50	15	.	.	.
cord-275349-b35pt3mo	51	1	Conflicts	conflict	NNS
cord-275349-b35pt3mo	51	2	that	that	WDT
cord-275349-b35pt3mo	51	3	the	the	DT
cord-275349-b35pt3mo	51	4	editors	editor	NNS
cord-275349-b35pt3mo	51	5	consider	consider	VBP
cord-275349-b35pt3mo	51	6	relevant	relevant	JJ
cord-275349-b35pt3mo	51	7	to	to	IN
cord-275349-b35pt3mo	51	8	the	the	DT
cord-275349-b35pt3mo	51	9	content	content	NN
cord-275349-b35pt3mo	51	10	of	of	IN
cord-275349-b35pt3mo	51	11	the	the	DT
cord-275349-b35pt3mo	51	12	manuscript	manuscript	NN
cord-275349-b35pt3mo	51	13	have	have	VBP
cord-275349-b35pt3mo	51	14	been	be	VBN
cord-275349-b35pt3mo	51	15	disclosed	disclose	VBN
cord-275349-b35pt3mo	51	16	.	.	.
cord-275349-b35pt3mo	52	1	Baricitinib	Baricitinib	NNP
cord-275349-b35pt3mo	52	2	versus	versus	IN
cord-275349-b35pt3mo	52	3	placebo	placebo	NN
cord-275349-b35pt3mo	52	4	or	or	CC
cord-275349-b35pt3mo	52	5	adalimumab	adalimumab	NNS
cord-275349-b35pt3mo	52	6	in	in	IN
cord-275349-b35pt3mo	52	7	rheumatoid	rheumatoid	NN
cord-275349-b35pt3mo	52	8	arthritis	arthritis	NN
cord-275349-b35pt3mo	52	9	Baricitinib	Baricitinib	NNP
cord-275349-b35pt3mo	52	10	as	as	IN
cord-275349-b35pt3mo	52	11	potential	potential	JJ
cord-275349-b35pt3mo	52	12	treatment	treatment	NN
cord-275349-b35pt3mo	52	13	for	for	IN
cord-275349-b35pt3mo	52	14	2019-nCoV	2019-ncov	CD
cord-275349-b35pt3mo	52	15	acute	acute	JJ
cord-275349-b35pt3mo	52	16	respiratory	respiratory	JJ
cord-275349-b35pt3mo	52	17	disease	disease	NN
cord-275349-b35pt3mo	52	18	Mechanism	Mechanism	NNP
cord-275349-b35pt3mo	52	19	of	of	IN
cord-275349-b35pt3mo	52	20	baricitinib	baricitinib	NNP
cord-275349-b35pt3mo	52	21	supports	support	VBZ
cord-275349-b35pt3mo	52	22	artificial	artificial	JJ
cord-275349-b35pt3mo	52	23	intelligencepredicted	intelligencepredicte	VBN
cord-275349-b35pt3mo	52	24	testing	testing	NN
cord-275349-b35pt3mo	52	25	in	in	IN
cord-275349-b35pt3mo	52	26	COVID-19	COVID-19	NNP
cord-275349-b35pt3mo	52	27	patients	patient	NNS
cord-275349-b35pt3mo	52	28	Efficacy	Efficacy	NNP
cord-275349-b35pt3mo	52	29	and	and	CC
cord-275349-b35pt3mo	52	30	safety	safety	NN
cord-275349-b35pt3mo	52	31	of	of	IN
cord-275349-b35pt3mo	52	32	baricitinib	baricitinib	NN
cord-275349-b35pt3mo	52	33	in	in	IN
cord-275349-b35pt3mo	52	34	Japanese	japanese	JJ
cord-275349-b35pt3mo	52	35	patients	patient	NNS
cord-275349-b35pt3mo	52	36	with	with	IN
cord-275349-b35pt3mo	52	37	active	active	JJ
cord-275349-b35pt3mo	52	38	rheumatoid	rheumatoid	NN
cord-275349-b35pt3mo	52	39	arthritis	arthritis	NN
cord-275349-b35pt3mo	52	40	receiving	receive	VBG
cord-275349-b35pt3mo	52	41	background	background	NN
cord-275349-b35pt3mo	52	42	methotrexate	methotrexate	NNP
cord-275349-b35pt3mo	52	43	therapy	therapy	NN
cord-275349-b35pt3mo	52	44	:	:	:
cord-275349-b35pt3mo	53	1	a	a	DT
cord-275349-b35pt3mo	53	2	12-week	12-week	JJ
cord-275349-b35pt3mo	53	3	,	,	,
cord-275349-b35pt3mo	53	4	double	double	JJ
cord-275349-b35pt3mo	53	5	-	-	HYPH
cord-275349-b35pt3mo	53	6	blind	blind	JJ
cord-275349-b35pt3mo	53	7	,	,	,
cord-275349-b35pt3mo	53	8	randomized	randomized	JJ
cord-275349-b35pt3mo	53	9	placebo	placebo	NN
cord-275349-b35pt3mo	53	10	-	-	HYPH
cord-275349-b35pt3mo	53	11	controlled	control	VBN
cord-275349-b35pt3mo	53	12	study	study	NN
cord-275349-b35pt3mo	53	13	Rapid	Rapid	NNP
cord-275349-b35pt3mo	53	14	systematic	systematic	JJ
cord-275349-b35pt3mo	53	15	review	review	NN
cord-275349-b35pt3mo	53	16	on	on	IN
cord-275349-b35pt3mo	53	17	clinical	clinical	JJ
cord-275349-b35pt3mo	53	18	evidence	evidence	NN
cord-275349-b35pt3mo	53	19	of	of	IN
cord-275349-b35pt3mo	53	20	chloroquine	chloroquine	NNP
cord-275349-b35pt3mo	53	21	and	and	CC
cord-275349-b35pt3mo	53	22	hydroxychloroquine	hydroxychloroquine	NN
cord-275349-b35pt3mo	53	23	in	in	IN
cord-275349-b35pt3mo	53	24	COVID-19	COVID-19	NNP
cord-275349-b35pt3mo	53	25	critical	critical	JJ
cord-275349-b35pt3mo	53	26	assessment	assessment	NN
cord-275349-b35pt3mo	53	27	and	and	CC
cord-275349-b35pt3mo	53	28	recommendation	recommendation	NN
cord-275349-b35pt3mo	53	29	for	for	IN
cord-275349-b35pt3mo	53	30	future	future	JJ
cord-275349-b35pt3mo	53	31	clinical	clinical	JJ
cord-275349-b35pt3mo	53	32	trials	trial	NNS
cord-275349-b35pt3mo	53	33	Baricitinib	Baricitinib	NNP
cord-275349-b35pt3mo	53	34	therapy	therapy	NN
cord-275349-b35pt3mo	53	35	in	in	IN
cord-275349-b35pt3mo	53	36	COVID-19	COVID-19	NNP
cord-275349-b35pt3mo	53	37	:	:	:
cord-275349-b35pt3mo	53	38	a	a	DT
cord-275349-b35pt3mo	53	39	pilot	pilot	NN
cord-275349-b35pt3mo	53	40	study	study	NN
cord-275349-b35pt3mo	53	41	on	on	IN
cord-275349-b35pt3mo	53	42	safety	safety	NN
cord-275349-b35pt3mo	53	43	and	and	CC
cord-275349-b35pt3mo	53	44	clinical	clinical	JJ
cord-275349-b35pt3mo	53	45	impact	impact	NN
cord-275349-b35pt3mo	53	46	Retrospective	Retrospective	NNP
cord-275349-b35pt3mo	53	47	,	,	,
cord-275349-b35pt3mo	53	48	multicenter	multicenter	JJ
cord-275349-b35pt3mo	53	49	study	study	NN
cord-275349-b35pt3mo	53	50	on	on	IN
cord-275349-b35pt3mo	53	51	the	the	DT
cord-275349-b35pt3mo	53	52	impact	impact	NN
cord-275349-b35pt3mo	53	53	of	of	IN
cord-275349-b35pt3mo	53	54	baricitinib	baricitinib	NN
cord-275349-b35pt3mo	53	55	in	in	IN
cord-275349-b35pt3mo	53	56	COVID-19	covid-19	JJ
cord-275349-b35pt3mo	53	57	moderate	moderate	JJ
cord-275349-b35pt3mo	53	58	pneumonia	pneumonia	NN
cord-275349-b35pt3mo	54	1	The	the	DT
cord-275349-b35pt3mo	54	2	potential	potential	JJ
cord-275349-b35pt3mo	54	3	role	role	NN
cord-275349-b35pt3mo	54	4	of	of	IN
cord-275349-b35pt3mo	54	5	IL-6	IL-6	NNP
cord-275349-b35pt3mo	54	6	in	in	IN
cord-275349-b35pt3mo	54	7	monitoring	monitor	VBG
cord-275349-b35pt3mo	54	8	coronavirus	coronavirus	NN
cord-275349-b35pt3mo	54	9	disease	disease	NN
cord-275349-b35pt3mo	54	10	2019	2019	CD
cord-275349-b35pt3mo	54	11	Clinical	clinical	JJ
cord-275349-b35pt3mo	54	12	predictors	predictor	NNS
cord-275349-b35pt3mo	54	13	of	of	IN
cord-275349-b35pt3mo	54	14	mortality	mortality	NN
cord-275349-b35pt3mo	54	15	due	due	IN
cord-275349-b35pt3mo	54	16	to	to	IN
cord-275349-b35pt3mo	54	17	COVID-19	COVID-19	NNP
cord-275349-b35pt3mo	54	18	based	base	VBN
cord-275349-b35pt3mo	54	19	on	on	IN
cord-275349-b35pt3mo	54	20	an	an	DT
cord-275349-b35pt3mo	54	21	analysis	analysis	NN
cord-275349-b35pt3mo	54	22	of	of	IN
cord-275349-b35pt3mo	54	23	data	datum	NNS
cord-275349-b35pt3mo	54	24	of	of	IN
cord-275349-b35pt3mo	54	25	150	150	CD
cord-275349-b35pt3mo	54	26	patients	patient	NNS
cord-275349-b35pt3mo	54	27	from	from	IN
cord-275349-b35pt3mo	54	28	Wuhan	Wuhan	NNP
cord-275349-b35pt3mo	54	29	,	,	,
cord-275349-b35pt3mo	54	30	China	China	NNP
cord-275349-b35pt3mo	54	31	Immune	Immune	NNP
cord-275349-b35pt3mo	54	32	mechanisms	mechanism	NNS
cord-275349-b35pt3mo	54	33	of	of	IN
cord-275349-b35pt3mo	54	34	pulmonary	pulmonary	JJ
cord-275349-b35pt3mo	54	35	intravascular	intravascular	JJ
cord-275349-b35pt3mo	54	36	coagulopathy	coagulopathy	NN
cord-275349-b35pt3mo	54	37	in	in	IN
cord-275349-b35pt3mo	54	38	COVID-19	COVID-19	NNP
cord-275349-b35pt3mo	54	39	pneumonia	pneumonia	NN
cord-275349-b35pt3mo	54	40	Pulmonary	Pulmonary	NNP
cord-275349-b35pt3mo	54	41	vascular	vascular	JJ
cord-275349-b35pt3mo	54	42	endothelialitis	endothelialitis	NN
cord-275349-b35pt3mo	54	43	,	,	,
cord-275349-b35pt3mo	54	44	thrombosis	thrombosis	NN
cord-275349-b35pt3mo	54	45	,	,	,
cord-275349-b35pt3mo	54	46	and	and	CC
cord-275349-b35pt3mo	54	47	angiogenesis	angiogenesis	NN
cord-275349-b35pt3mo	54	48	in	in	IN
cord-275349-b35pt3mo	54	49	Covid-19	Covid-19	NNP
cord-275349-b35pt3mo	54	50	Effect	Effect	NNP
cord-275349-b35pt3mo	54	51	of	of	IN
cord-275349-b35pt3mo	54	52	dexamethasone	dexamethasone	NN
cord-275349-b35pt3mo	54	53	in	in	IN
cord-275349-b35pt3mo	54	54	hospitalized	hospitalize	VBN
cord-275349-b35pt3mo	54	55	patients	patient	NNS
cord-275349-b35pt3mo	54	56	with	with	IN
cord-275349-b35pt3mo	54	57	COVID-19	COVID-19	NNP
cord-275349-b35pt3mo	54	58	:	:	:
cord-275349-b35pt3mo	54	59	preliminary	preliminary	JJ
cord-275349-b35pt3mo	54	60	report	report	NN